

Vax Facts – Endnotes

1. Thomas MD, Paul, and Jennifer Margulis PhD. 2016. *The Vaccine-Friendly Plan: Dr. Paul's Safe and Effective Approach to Immunity and Health—From Pregnancy Through Your Child's Teen Years*. New York: Ballantine Books.
2. Centers for Disease Control and Prevention. 2024. "Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States 2024." [cdc.gov. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html](https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html)
3. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
4. Offit, Paul. 2017. "The Unhealthiest State in America Has the Best Vaccination Rate." *Daily Beast*, December 15. <https://www.thedailybeast.com/the-unhealthiest-state-in-america-has-the-best-vaccination-rate>
5.
 1. "ICAN's Monumental Mississippi Win Legal Update." Informed Consent Action Network. April 21. <https://icandecide.org/press-release/icans-monumental-mississippi-win/>
6. Centers for Disease Control and Prevention. 2023. "Vaccine Information Statements (VISs)—Current VISs." [cdc.gov. December 7. https://www.cdc.gov/vaccines/hcp/vis/current-vis.html](https://www.cdc.gov/vaccines/hcp/vis/current-vis.html)
7. Centers for Disease Control and Prevention. 2009. "Healthcare Professionals / Providers—Q&As about Monovalent M-M-R Vaccines." October 26. <https://www.cdc.gov/vaccines/hcp/clinical-resources/mmr-faq-12-17-08.html>
8. Edwards MD, Kathryn M., and Jesse M. Hackell MD. 2016. "Countering Vaccine Hesitancy—Guidance for the Clinician in Rendering Pediatric Care." *Pediatrics* (The American Academy of Pediatrics) 138 (3). <https://doi.org/10.1542/peds.2016-2146>
9.
 1. The Control Group. <https://www.thecontrolgroup.org/>
10. Stoner, Alexis M., Sarah E. Anderson, and Timothy J. Buckley. 2013. "Ambient Air Toxics and Asthma Prevalence among a Representative Sample of US Kindergarten-Age Children." *PLoS One* 8 (9). <https://doi.org/10.1371/journal.pone.0075176>
11. Jackson, Kristen D., LaJeana D. Howie, and Lara J. Akinbami. 2013. "Trends in Allergic Conditions among Children: United States, 1997–

- 2011." *NCHS Data Brief* (121): 1–8. <https://pubmed.ncbi.nlm.nih.gov/23742874/>
12. Food Allergy Research & Education. 2017. "FAIR Health Reports That Food Allergy Prevalence, Treatment and Costs Have Skyrocketed in Past Decade." FARE. November 22. <https://www.foodallergy.org/media-room/fair-health-reports-food-allergy-prevalence-treatment-and-costs-have-skyrocketed-past>
 13. Zablotsky, Benjamin, Lindsey I. Black, and Stephen J. Blumberg. 2017. "Estimated Prevalence of Children with Diagnosed Developmental Disabilities in the United States, 2014–2016." *NCHS Data Brief* (291): 1–8. <https://pubmed.ncbi.nlm.nih.gov/29235982/>
 14. Rowland, Andrew S., Betty J. Skipper, and Dale P. Sandler. 2015. "The Prevalence of ADHD in a Population-Based Sample." *Journal of Attention Disorders* 19 (9): 741–754. <https://doi.org/10.1177%2F1087054713513799>
 15. Dabelea, Dana, Elizabeth J. Mayer-Davis, Sharon Saydah, Giuseppina Imperatore, Barbara Linder, Jasmin Divers, Ronny Bell, et al. 2014. "Prevalence of Type 1 and Type 2 Diabetes among Children and Adolescents from 2001 to 2009." *JAMA* 311 (17): 1778–1786. <https://doi.org/10.1001%2Fjama.2014.3201>
 16. Cunningham, Solveig A., Ashlesha Datar, K.M. Venkat Narayan, and Michael R. Kramer. 2017. "Entrenched Obesity in Childhood: Findings from a National Cohort Study." *Annals of Epidemiology* 27 (7): 435–441. <https://doi.org/10.1016/j.annepidem.2017.05.016>
 17. Kelly, Adams M., Martin Kohlmeier, and Steven Zeisel. 2010. "Nutrition Education in U.S. Medical Schools: Latest Update of a National Survey." *Academic Medicine* 85 (9): 1537–1542. <https://doi.org/10.1097/acm.0b013e3181eab71b>
 18. Humphries MD, Suzanne, and Roman Bystryanyk. 2013. *Dissolving Illusions: Disease, Vaccines, and the Forgotten History*. CreateSpace Independent Publishing Platform.
 19. Wakefield, Andrew J., S. H. Murch, A. Anthony, J. Linnell, D. M. Casson, M. Malik, M. Berelowitz, et al. 1998. "Ileal-lymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in Children." *The Lancet* 351 (9103): 637–641. [https://doi.org/10.1016/S0140-6736\(97\)11096-0](https://doi.org/10.1016/S0140-6736(97)11096-0)
 20. Sharav, Vera. 2023. "L'affaire Wakefield: Shades of Dreyfus & BMJ's Descent into Tabloid Science." Alliance for Human Research Protection (AHRP). October 30. <https://ahrp.org/laffaire-wakefield-introduction/>
 21. Autism Research Institute. 2024. <https://autism.org/>
 22. Kirby, David. 2006. *Evidence of Harm: Mercury in Vaccines and the Autism Epidemic: A Medical Controversy*. St. Martin's Griffin.
 23. Olmstead, Susan C. 2022. "Chronic Disease Among Kids 'Skyrocketing,' Pediatrician Tells RFK Jr." *The Defender*, June

22. <https://childrenshealthdefense.org/defender/chronic-disease-kids-pediatrician-dr-joel-gator-warsh-rfk-jr-podcast/>
24. Shoenfeld, Yehuda, Nancy Agmon-Levin, and Lucija Tomljenovic. 2015. *Vaccines and Autoimmunity*. Wiley-Blackwell.
25. Hooker, Brian S. Winter 2018. "Reanalysis of CDC Data on Autism Incidence and Time of First MMR Vaccination." *Journal of American Physicians and Surgeons* 23 (4): 105–109. <https://www.jpands.org/vol23no4/hooker.pdf>
26. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
27. Hammond, Jeremy R. 2021. *The War on Informed Consent: The Persecution of Dr. Paul Thomas by the Oregon Medical Board*. Skyhorse Publishing. <https://www.jeremyrhammond.com/product/the-war-on-informed-consent/>
28. Lyons-Weiler, James, and Russell L. Blaylock. 2022. "Revisiting Excess Diagnoses of Illnesses and Conditions in Children Whose Parents Provided Informed Permission to Vaccinate Them." *International Journal of Vaccine Theory, Practice, and Research* 2 (2): 603–618. <http://dx.doi.org/10.56098/ijvtpr.v2i2.59>
- 29.
1. "Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011)." JUSTIA U.S. Supreme Court. February 22. <https://supreme.justia.com/cases/federal/us/562/223/>
- 30.
1. "VAERS COVID Vaccine Adverse Event Reports." OpenVAERS. <https://openvaers.com/covid-data>
31. Kory, Pierre, and Jenna McCarthy. 2023. *The War on Ivermectin: The Medicine That Saved Millions and Could Have Ended the Pandemic*. Skyhorse Publishing.
32. Ioannidis, John P.A. 2021. "Infection Fatality Rate of COVID-19 Inferred from Seroprevalence Data." *Bulletin of the World Health Organization* 99 (1): 19–33. <https://doi.org/10.2471%2FBLT.20.265892>
33. Clark, Ross. 2020. "Stanford Study Suggests Coronavirus Might Not Be as Deadly as Flu." *The Spectator*, May 20. <https://www.spectator.co.uk/article/stanford-study-suggests-coronavirus-might-not-be-as-deadly-as-flu/>
- 34.
1. "Ex-Health Ministry Chief: 'You're Not More at Risk of Dying of Coronavirus Than the Flu'." *Israel National News*. May 26. <https://www.israelnationalnews.com/news/280874>

4 | vAx FACTS

35. Levin, Andrew T., William P. Hanage, Nana Owusu-Boaitey, Kensington B. Cochran, Seamus P. Walsh, and Gideon Meyerowitz-Katz. 2020. "Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-analysis, and Public Policy Implications." *European Journal of Epidemiology* 35: 1123–1138. <https://doi.org/10.1007%2Fs10654-020-00698-1>
36.
 1. "DoD COVID-19 Vaccine Distribution." U.S. Department of Defense. December 9. <https://media.defense.gov/2020/Dec/09/2002548827/-1/-1/0/DOD-COVID-19-VACCINE-DISTRIBUTION-PLAN-AND-POPULATION-SCHEMA.PDF>
37. Kennedy Jr., Robert F. 2023. *The Wuhan Cover-Up: And the Terrifying Bioweapons Arms Race*. Skyhorse Publishing.
38. Miller, Mark Crispin. 2024. "News from Underground (NFU)." Mark Crispin Miller on Substack. <https://substack.com/@markcrispinmiller1>
39. McCullough, Peter. 2023. "The Global mRNA Patent Frenzy." *Courageous Discourse™* on Substack. August 22. <https://petermcculloughmd.substack.com/p/the-global-mrna-patent-frenzy>
40. Kennedy Jr., Robert F. 2021. *The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health*. Skyhorse Publishing.
41. Leake, John, Peter A. McCullough, and Robert F. Kennedy Jr. 2022. *The Courage to Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex*. Skyhorse Publishing.
42. Mercola, Dr. Joseph, and Ronnie Cummins. 2021. *The Truth about COVID-19: Exposing the Great Reset, Lockdowns, Vaccine Passports, and the New Normal*. Chelsea Green Publishing.
43.
 1. CHD.TV. <https://live.childrenshealthdefense.org/chd-tv/>
44.
 1. *The Defender*. <https://childrenshealthdefense.org/defender/>
45.
 1. The Highwire. <https://thehighwire.com/>
46. Thomas, Dr. Paul, and DeeDee Hoover. 2024. "Kids First 4 Ever: Dr Paul and DeeDee." Kids First 4 Ever on Substack. <https://kidsfirst4ever.substack.com/>
47. Joanna, Regan J., Danielle L. Moulia, Ruth Link-Gelles, Monica Godfrey, Josephine Mak, Morgan Najdowski, et al. 2023. "Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged \geq 6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States." *MMWR: Recommendations*

- and Reports* 72 (42): 1140–1146. <https://www.cdc.gov/mmwr/volumes/72/wr/mm7242e1.htm>
48. Shitrit, P., N. S. Zuckerman, O. Mor, B. S. Gottesman, and M. Chowers. 2021. "Nosocomial Outbreak Caused by the SARS-CoV-2 Delta Variant in a Highly Vaccinated Population, Israel, July 2021." *Euro Surveillance* 26 (39). <https://doi.org/10.2807/1560-7917.es.2021.26.39.2100822>
 49. Subramanian, S. V., and A. Kumar. 2021. "Increases in COVID-19 are Unrelated to Levels of Vaccination across 68 Countries and 2947 Counties in the United States." *European Journal of Epidemiology* 36: 1237–1240. <https://doi.org/10.1007/s10654-021-00808-7>
 50. Fraiman, J., et al. 2022. "Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults." *Vaccine* (2022) 40 (40): 5798–805. <https://doi.org/10.1016/j.vaccine.2022.08.036>
 51.
 1. "FDA Briefing Document: EUA Amendment Request for Pfizer-BioNTech COVID-19 Vaccine for Use in Children 5 Through 11 Years of Age." [fda.gov](https://www.fda.gov/media/153447/download). October 26. <https://www.fda.gov/media/153447/download>
 52. Wallace, Megan. 2021. "ACIP COVID-19 Vaccines Work Group: Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine." [cdc.gov](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/03-COVID-Wallace-508.pdf). May 12. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/03-COVID-Wallace-508.pdf>
 53. Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. 2021. "Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12–15 Years." [cdc.gov](https://www.cdc.gov/vaccines/acip/recs/grade/covid19-pfizer-biontech-vaccine-12-15-years.html#table03d). May 14. <https://www.cdc.gov/vaccines/acip/recs/grade/covid19-pfizer-biontech-vaccine-12-15-years.html#table03d>
 54. Pfizer. 2022. "Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccines (12 Years and Older): Table 11 Vaccine Efficacy—First COVID-19 Occurrence from 7 Days...Adolescents 12 Through 15 Years of Age Evaluable Efficacy (7 Days) Population." [fda.gov](https://www.fda.gov/media/153713/download) via [archive.org](https://web.archive.org/web/20220118183423/fda.gov/media/153713/download). January 3. <https://web.archive.org/web/20220118183423/fda.gov/media/153713/download>
 55. Ioannidis, John P.A. 2021. "Reconciling Estimates of Global Spread and Infection Fatality Rates of COVID-19: An Overview of Systematic Evaluations." *European Journal of Clinical Investigation* 51 (5). <https://doi.org/10.1111/eci.13554>

56.

1. "Physicians for Informed Consent COVID-19: Disease Information Statement (DIS)." Physicians for Informed Consent.

August. <https://physiciansforinformedconsent.org/wp-content/uploads/2021/08/PIC-COVID-19-Disease-Information-Statement-DIS-August-2021.pdf>

57. Ed Dowd. 2024. *Cause Unknown: The Epidemic of Sudden Deaths in 2021, 2022, and 2023*. Skyhorse Publishing.
58. Lyons-Weiler, James, and Paul Thomas. 2021. "Vaccine Practice Payment Schedules Create Perverse Incentives for Unnecessary Medical Procedures—at What Cost to Patients?" *International Journal of Vaccine Theory, Practice, and Research* 2 (1). <https://doi.org/10.56098/ijvtpr.v2i1.21>
59. Mayo Clinic. 2006. "Harnessing the Measles Virus to Attack Cancer." *Science Daily*, October 31. <https://www.sciencedaily.com/releases/2006/10/061030143318.htm>
60. Rønne, Tove. 1985. "Measles Virus Infection without Rash in Childhood Is Related to Disease in Adult Life." *The Lancet* 325 (8419): 1–5. [https://doi.org/10.1016/S0140-6736\(85\)90961-4](https://doi.org/10.1016/S0140-6736(85)90961-4)
61. Sasco, Annie J., and Ralph S. Paffenbarger Jr. 1985. "Measles Infection and Parkinson's Disease." *American Journal of Epidemiology* 122 (6): 1017–1031. <https://doi.org/10.1093/oxfordjournals.aje.a114183>
62. Parodi, Stefano, et al. 2013. "Childhood Infectious Diseases and Risk of Leukaemia in an Adult Population." *International Journal of Cancer* 133 (8): 1892–1899. <https://doi.org/10.1002/ijc.28205>
63. Shaheen, S. O., et al. 1996. "Measles and Atopy in Guinea-Bissau." *The Lancet* 347 (9018): 1792–1796. [https://doi.org/10.1016/s0140-6736\(96\)91617-7](https://doi.org/10.1016/s0140-6736(96)91617-7)
64. Rosenlund, Helen, et al. 2009. "Allergic Disease and Atopic Sensitization in Children in Relation to Measles Vaccination and Measles Infection." *Pediatrics* 123 (3): 771–778. <https://doi.org/10.1542/peds.2008-0013>
65. Montella, Maurizio. 2006. "Do Childhood Diseases Affect NHL and HL Risk? A Case-Control Study from Northern and Southern Italy." *Leukemia Research* 30 (8): 917–922. <https://doi.org/10.1016/j.leukres.2005.11.020>
66. Kubota, Yasuhiko, Hiroyasu Iso, and Akiko Tamakoshi. 2015. "Association of Measles and Mumps with Cardiovascular Disease: The Japan Collaborative Cohort (JACC) Study." *Atherosclerosis* 241 (2): 682–686. <https://doi.org/10.1016/j.atherosclerosis.2015.06.026>
67. Cramer, D. W., et al. 2010. "Mumps and Ovarian Cancer: Modern

- Interpretation of an Historic Association." *Cancer Causes Control* 21 (8): 1193–1201. <https://doi.org/10.1007/s10552-010-9546-1>
68. Albonico, H. U., H. U. Braker, and J. Hüsler. 1998. "Febrile Infectious Childhood Diseases in the History of Cancer Patients and Matched Control." *Medical Hypotheses* 51 (4): 315–320. [https://doi.org/10.1016/S0306-9877\(98\)90055-X](https://doi.org/10.1016/S0306-9877(98)90055-X)
69. Alexander, F., et al. 2000. "Risk Factors for Hodgkin's Disease by Epstein-Barr Virus (EBV) Status: Prior Infection by EBV and Other Agents." *British Journal of Cancer* 82 (5): 1117–1121. <https://doi.org/10.1054/bjoc.1999.1049>
70. Aref, Sarah, Katharine Bailey, and Adele Fielding. 2016. "Measles to the Rescue: A Review of Oncolytic Measles Virus." *Viruses* 8 (10): 294. <https://doi.org/10.3390/v8100294>
71. Gilham, C., et al. 2005. "Day Care in Infancy and Risk of Childhood Acute Lymphoblastic Leukaemia: Findings from UK Case-Control Study." *BMJ* 330: 1294. <https://doi.org/10.1136/bmj.38428.521042.8F>
72. Urayama, Kevin Y., et al. 2011. "Early Life Exposure to Infections and Risk of Childhood Acute Lymphoblastic Leukemia." *International Journal of Cancer* 128 (7): 1632–1643. <https://doi.org/10.1002/ijc.25752>
73. Silverberg, Jonathan I., et al. 2012. "Chickenpox in Childhood Is Associated with Decreased Atopic Disorders, IgE, Allergic Sensitization, and Leukocyte Subsets." *Pediatric Allergy and Immunology* 23 (1): 50–58. <https://doi.org/10.1111/j.1399-3038.2011.01224.x>
74. Hopton Cann, Stephen A., J. P. van Netten, and C. van Netten. 2006. "Acute Infections as a Means of Cancer Prevention: Opposing Effects to Chronic Infections?" *Cancer Detection and Prevention* 30 (1): 83–93. <https://doi.org/10.1016/j.cdp.2005.11.001>
75. Olszak, Torsten, et al. 2012. "Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function." *Science* 336 (6080): 489–493. <https://doi.org/10.1126/science.1219328>
76. Amirian, E. Susan, et al. 2016. "History of Chickenpox in Glioma Risk: A Report from the Glioma International Case-Control Study (GICC)." *Cancer Medicine* 5 (6): 1352–1358. <https://doi.org/10.1002/cam4.682>
77. Iheagwara, Uzoma K., et al. 2014. "Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance." *Cancer Immunology Research* 2 (3): 263–273. <https://doi.org/10.1158/2326-6066.CIR-13-0125>
78. Newhouse, Muriel L., et al. 1977. "A Case Control Study of Carcinoma of the Ovary." *British Journal of Preventive & Social*

- Medicine* 31: 148–153. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC479015/pdf/brjprevsmed00027-0012.pdf>
79. Boraschi, Diana, Paola Italiani, Roberto Palomba, Paolo Decuzzi, Albert Duschl, Bengt Fadeel, and S. Moein Moghimi. 2017. "Nanoparticles and Innate Immunity: New Perspectives on Host Defence." *Seminars in Immunology* 34: 33–51. <https://www.sciencedirect.com/science/article/abs/pii/S1044532317300441>
80. Shrestha, N. K., P. C. Burke, A. S. Nowacki, J. F. Simon, et al. 2023. "Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine." *Open Forum Infectious Diseases* 10 (6). <https://doi.org/10.1093/ofid/ofad209>
81. Shrestha, N. K., P. C. Burke, A. S. Nowacki, P. Terpeluk, and S. M. Gordon. 2021. "Necessity of COVID-19 Vaccination in Previously Infected Individuals." *medRxiv*. <https://doi.org/10.1101/2021.06.01.21258176>
82. Kojima, N., N. K. Shrestha, and J. D. Klausner. 2021. "A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection." *Evaluation & the Health Professions* 44 (4): 327–332. <https://doi.org/10.1177/01632787211047932>
83. Abu-Raddad, L. J., H. Chemaitelly, P. Coyle, et al. 2021. "SARS-CoV-2 Antibody-positivity Protects against Reinfection for at Least Seven Months with 95% Efficacy." *EclinicalMedicine* 35. <https://www.sciencedirect.com/science/article/pii/S2589537021001413>
84. Harvey, R. A., J. A. Rassen, C. A. Kabelac, et al. 2021. "Association of SARS-CoV-2 Seropositive Antibody Test with Risk of Future Infection." *JAMA Internal Medicine* 181 (5): 672–679. <https://doi.org/10.1001%2Fjamainternmed.2021.0366>
85. Jeffery-Smith, A., N. Iyanger, S. V. Williams, et al. 2021. "Antibodies to SARS-CoV-2 Protect against Re-infection during Outbreaks in Care Homes, September and October 2020." *Euro Surveillance* 26 (5). <https://doi.org/10.2807/1560-7917.ES.2021.26.5.2100092>
86. Qureshi, A. I., W. I. Baskett, W. Huang, et al. 2022. "Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing." *Clinical Infectious Diseases* 74 (2): 294–300. <https://doi.org/10.1093/cid/ciab345>
87. Vojdani, Aristo, Elroy Vojdani, and Datis Khar. 2020. "Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins with Tissue Antigens: Implications for Autoimmune Diseases." *Frontiers in Immunology, Section: Autoimmune and Autoinflammatory Disorders* 11. <https://doi.org/10.3389/fimmu.2020.617089>

88. Moskowitz MD, Richard. 2017. *Vaccines: A Reappraisal*. Skyhorse Publishing.
89. Kennedy Jr., Robert F., M. Hyman, et al. 2015. *Thimerosal: Let the Science Speak: The Evidence Supporting the Immediate Removal of Mercury—a Known Neurotoxin—from Vaccines*. Skyhorse Publishing.
90. Albonico, H. U., H. U. Braker, and J. Hüsler. 1998. "Febrile Infectious Childhood Diseases in the History of Cancer Patients and Matched Control." *Medical Hypotheses* 51 (4): 315–320. [https://doi.org/10.1016/S0306-9877\(98\)90055-X](https://doi.org/10.1016/S0306-9877(98)90055-X)
91. Blaylock, R. L. 2012. "Aluminum Induced Immunoexcitotoxicity in Neurodevelopmental and Neurodegenerative Disorders." *Current Inorganic Chemistry* 2 (1): 46–53. <https://www.eurekaselect.com/article/41192>
92. Blaylock, R. L. 2009. "A Possible Central Mechanism in Autism Spectrum Disorders, Part 2: Immunoexcitotoxicity." *Alternative Therapies in Health and Medicine* 15 (1): 60–67. <https://pubmed.ncbi.nlm.nih.gov/19161050/>
93. Blaylock, R. L., and A. Strunecka. 2009. "Immune-glutamatergic Dysfunction as a Central Mechanism of Autism Spectrum Disorders." *Current Medicinal Chemistry* 16 (2): 157–170. <https://www.eurekaselect.com/article/13246>
94. Blaylock, R. L. 2003. "The Central Role of Excitotoxicity in Autism Spectrum Disorders." *Journal of the American Nutraceutical Association* 6 (1): 10–22.
95. Blaylock, R. L. 2004. "Excitotoxicity: A Possible Central Mechanism in Fluoride Neurotoxicity." *Fluoride* 37 (4): 301–314. https://www.researchgate.net/publication/282499179_Excitotoxicity_A_possible_central_mechanism_in_fluoride_neurotoxicity
96. Blaylock, R. L. 2023. "The Biochemical Basis of Neurodegenerative Disease: The Role of Immunoexcitotoxicity and Possible Ways to Attenuate It." *Surgical Neurology International* 12 (141).
97. Blaylock, R. L., and M. Faria. 2021. "New Concepts in the Development of Schizophrenia, Autism Spectrum Disorders, and Degenerative Brain Diseases Based on Chronic Inflammation: A Working Hypothesis from Continued Advances in Neuroscience Research." *Surgical Neurology International* 12 (556). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645502/>
98. Strunecka, A., R. L. Blaylock, M. A. Hyman, and I. Paclt. 2010. *Cellular and Molecular Biology of Autism Spectrum Disorders*. Edited by Anna Strunecka. Bentham Science Publishers.
99. Strunecka, A., R. L. Blaylock, J. Patocka, and O. Strunecky. 2018. "Immunoexcitotoxicity as the Central Mechanism of Etiopathology and Treatment of Autism Spectrum Disorders: A Possible Role of Fluoride and Aluminum." *Surgical Neurology International* 9:

74. <https://surgicalneurologyint.com/surgicalint-articles/immunoexcitotoxicity-as-the-central-mechanism-of-etiopathology-and-treatment-of-autism-spectrum-disorders-a-possible-role-of-fluoride-and-aluminum/>
100. Tomljenovic, Lucija, and Christopher A. Shaw. 2011. "Aluminum Vaccine Adjuvants: Are They Safe?" *Current Medicinal Chemistry* 18 (17): 2630–2637. <https://doi.org/10.2174/092986711795933740>
101. Exley PhD, Christopher. 2020. *Imagine You Are an Aluminum Atom: Discussions with Mr. Aluminum*. Skyhorse Publishing.
102. Tian, Ayong, et al. 2015. "Vitamin D Improves Cognitive Function and Modulates Th17/Treg Cell Balance after Hepatectomy in Mice." *Inflammation* 38: 500–509. <https://doi.org/10.1007/s10753-014-9956-4>
103. Ranganathan, P. 2009. "Genetics of Bone Loss in Rheumatoid Arthritis—Role of Vitamin D Receptor Polymorphisms." *Rheumatology* 48 (4): 342–346. <https://doi.org/10.1093/rheumatology/ken473>
104. FLCCC Alliance. 2023. "I-RECOVER Post-Vaccine Protocol." FLCCC Alliance. July 24. <https://covid19criticalcare.com/protocol/i-recover-post-vaccine-treatment/>
105. 1. "Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011)." JUSTIA U.S. Supreme Court. February 22. <https://supreme.justia.com/cases/federal/us/562/223/>
106. Olins, Jessica, ed. 2023. "Information about Vaccine Injury Payouts: The Vaccine Injury Compensation Program (NVICP)." *mctlaw.com*. November 3. <https://www.mctlaw.com/vaccine-injury/info-about-vaccine-injury-payouts/>
107. Centers for Disease Control and Prevention. 2015. *Epidemiology and Prevention of Vaccine-Preventable Diseases 13th ed. (The Pink Book)*. Edited by Jennifer Hamborsky, Andrew Kroger and Charles Wolfe. Washington D.C.: Public Health Foundation.
108. Centers for Disease Control and Prevention. National Center for Health Statistics. 2015. "Vital Statistics of the United States 1937–1960." *cdc.gov*. November 6. <https://www.cdc.gov/nchs/products/vsus.htm>
109. 1. "Historical Statistics of the United States, Colonial Times to 1970." United States Census Bureau. September. https://www.census.gov/library/publications/1975/compendia/hist_stats_colonial-1970.html

110. Humphries MD, Suzanne, and Roman Bystryanyk. 2013. *Dissolving Illusions: Disease, Vaccines, and the Forgotten History*. CreateSpace Independent Publishing Platform.
111. Seventh Biennial Report of the Board of Health of the State of Iowa. 1893. "The Causation and Prevention of Typhoid Fever." *JAMA* 58.
112. Porter, Roy. 1997. *The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present*. London: HarperCollins.
113. Streiner, David L., Douglas W. MacPherson, and Brian D. Gushulak. 2010. *PDQ Public Health*. PMPH USA.
114. 1. "Scarlatina Epidemics." *The British Medical Journal* 2 (141): 285–286. <https://www.jstor.org/stable/25200132>
115. *The New York Times*. 1855. "Yellow Fever—Fearful Progress of the Disease at Norfolk." September 11.
116. 1. "Increasing Output by Preventing Tuberculosis." *The American Contractor* (F.W. Dodge Corp.) 42: 366/30.
117. Hallett, Christine. 2005. "The Attempt to Understand Puerperal Fever in the Eighteenth and the Early Nineteenth Centuries: The Influence of Inflammation Theory." *Medical History* 49 (1): 1–28. <https://doi.org/10.1017/s0025727300000119>
118. *The Gentleman's Magazine and Historical Chronical*. 1764. "The Practice of Inoculation Truly Stated." 333.
119. Fenn, Elizabeth A. 2003. "The Great Smallpox Epidemic." *History Today*, August. <https://www.historytoday.com/archive/great-smallpox-epidemic>
120. Ratner, H., H. R. Cox, B. G. Greenberg, H. Kleinman, and P. Meier. 1960. "The Present Status of Polio Vaccines." *Illinois Medical Journal*, 84–93. <https://ia801206.us.archive.org/17/items/illinoismedicalj1171illi/iillinoismedicalj1171illi.pdf>
121. Centers for Disease Control and Prevention. 2022. "Smallpox—Vaccine Basics." cdc.gov. August 8. <https://www.cdc.gov/smallpox/vaccine-basics/index.html>
122. Flexner, Abraham. 1910. *Medical Education in the United States and Canada: A Report to the Carnegie Foundation for the Advancement of Teaching*. Boston: D.B. Updike, The Merrymount Press. http://archive.carnegiefoundation.org/publications/pdfs/elibrary/Carnegie_Flexner_Report.pdf
123. Gard, Sven. 1956. "Prophylactic Vaccination against Poliomyelitis." *Swedish Physician's Journal*. Translated for distribution by the Oak Park Health Department, Oak Park Illinois.

Provided by Herbert Ratner MD.

124. Qi, Fang, Michele Carbone, Haining Yang, and Giovanni Guadino. 2011. "Simian Virus 40 Transformation, Malignant Mesothelioma and Brain Tumors." *Expert Review of Respiratory Medicine* 5 (5): 683–697. <https://doi.org/10.1586%2Fers.11.51>
125. Centers for Disease Control and Prevention. 2023. "2023 Recommended Immunizations for Children from Birth Through 6 Years Old." <https://www.cdc.gov/vaccines/parents/downloads/parent-ver-sch-0-6yrs.pdf>
126. Anonymous. 2022. *Turtles All the Way Down: Vaccine Science and Myth*. Edited by Zoey O'Toole and Mary Holland. ISBN: 978-965-598-104-9. The Turtles Team.
127. Anonymous. 2022. *Turtles All the Way Down—References*. Edited by Zoey O'Toole and Mary Holland. <https://drive.google.com/file/d/16qHPe0odDOweuCDlwIEjaRf4Aiu7oyM9/view>
128. Sanofi Pasteur. "Package Insert: DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)." [fda.gov. https://www.fda.gov/media/74035/download](https://www.fda.gov/media/74035/download)
129. GlaxoSmithKline (GSK). 1997. "Package Insert: INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Suspension for Intramuscular Injection." [fda.gov. https://www.fda.gov/media/75157/download](https://www.fda.gov/media/75157/download)
130. Siri & Glimstad LLP. 2021. "January 28, 2021 Letter to Special Rapporteur on Extreme Poverty and Human Rights, Re: Death of Infants in Certain Developing Countries by Systematic Use of a Biologic." Informed Consent Action Network. January 28. <https://icandecide.org/wp-content/uploads/2021/06/2021.01.28-Letter-to-Special-Rapporteur-on-Poverty.pdf>
131.
 1. "The Swedish Trial: Clinical Review of Biological License Application DAPTACEL (CPDT)." April 9. <https://drive.google.com/file/d/1CFrePXwN-q5ywCnuflnwLjUwScsLPvBU/view>
132. Sanofi Pasteur. 2022. "Package Insert: ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] Solution for Intramuscular Injection." [fda.gov. March. https://www.fda.gov/media/74395/download](https://www.fda.gov/media/74395/download)
133. GlaxoSmithKline (GSK). 2009. "Package Insert: HIBERIX [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] for injection, for intramuscular use." [fda.gov. https://www.fda.gov/media/77017/download](https://www.fda.gov/media/77017/download)
134. FDA, Division of Vaccines and Related Products Applications. 2009. "Hiberix BLA Clinical Review." [fda.gov via archive-it.org. July 8. https://wayback.archive-](https://wayback.archive-it.org)

- [it.org/7993/20190930090059/https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Clinical-Review---July-8--2009--Hiberix.pdf](https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Clinical-Review---July-8--2009--Hiberix.pdf)
135. Merck & Co., Inc. 1998. "Package Insert: Liquid PedvaxHIB®." fda.gov. <https://www.fda.gov/media/80438/download>
 136. Sanofi Pasteur. 2022. "Package Insert: IPOL®, Poliovirus Vaccine Inactivated." fda.gov. May. <https://www.fda.gov/media/75695/download>
 137. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, et al. 2000. "Efficacy, Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Children." *The Pediatric Infectious Disease Journal* 19 (3): 187–195. https://journals.lww.com/pidj/abstract/2000/03000/efficacy_safety_and_immunogenicity_of_heptavalent.3.aspx
 138. Pfizer. 2010. "Package Insert: PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])." fda.gov. <https://www.fda.gov/media/107657/download>
 139. Merck & Co., Inc. 2021. "Package Insert: VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)." fda.gov. <https://www.fda.gov/media/150819/download>
 140. Pfizer. 2021. "Package Insert: PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine)." fda.gov. <https://www.fda.gov/media/149987/download>
 141. Mongeau, Tina Khoie. 2021. "BLA Clinical Review Memorandum: PREVNAR 20." fda.gov. June 8. <https://www.fda.gov/media/150459/download>
 142. GlaxoSmithKline (GSK). 2023. "Package Insert: ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use." gskpro.com. October. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Engerix-B/pdf/ENGERIX-B.PDF
 143.
 1. "FDA August 20, 2018 MMRII FOIA Response, re: file 2018-6847 (see clinical reports)." Siri & Glimstad LLC. March 27. <https://www.sirillp.com/wp-content/uploads/2023/07/MMRII-FOIA.pdf>
 144. GlaxoSmithKline (GSK). 2022. "Package Insert: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live)." fda.gov. <https://www.fda.gov/media/158941/download>
 145. Klein, Nicola P., et al. 2019. "Supplementary Materials: Immunogenicity and Safety of MMR Vaccine." ncbi.nlm.nih.gov. November 14. https://link.sbstck.com/redirect/874a1ea9-b86c-45ad-a49e-6978a20d9e8a?j=eyJ1Ijoicm5tMjUifQ.8Q4vB5un1FDjnCY46_-FvMQmk6OF4UZj6X51K1HITA

146. Ruiz-Palacios, Guillermo M., I. Pérez-Schael, F. Velázquez, H. Abate, Human Rotavirus Vaccine Study Group, et al. 2006. "Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis." *The New England Journal of Medicine* 354 (1): 11–22. <https://doi.org/10.1056/nejmoa052434>
147. GlaxoSmithKline (GSK). 2008. "Package Insert: ROTARIX (Rotavirus Vaccine, Live, Oral)." fda.gov. <https://www.fda.gov/media/163009/download>
148. FDA, Division of Vaccines and Related Products Applications. 2008. "Clinical Review for STN 125265/0 Rotarix: Rotavirus Vaccine, Live, Oral." fda.gov via archive-it.org. March 10. <https://wayback.archive-it.org/7993/20170722073219/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM133580.pdf>
149. Merck & Co., Inc. 2006. "Package Insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent)." fda.gov. <https://www.fda.gov/media/75718/download>
150. 1. "FDA May 8, 2018 RotaTeq placebo FOIA Response, re: file 2018-3994 (see clinical reports)." Informed Consent Action Network. June 14. https://icandecide.org/wp-content/uploads/2023/06/rotateq_placebo.pdf
151. Pfizer. 2023. "Package Insert: COMIRNATY® (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use 2023-2024 Formula." fda.gov. October. <https://www.fda.gov/media/151707/download>
152. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
153. Lazarus, Ross. 2010. *Electronic Support for Public Health—Vaccine Adverse Event Reporting System (ESP:VAERS)*. Grant Final Report, The Agency for Healthcare Research and Quality (AHRQ) U.S. Department of Health and Human Services, Boston: Harvard Pilgrim Health Care, Inc. <https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-public-health-vaccine-adverse-event-reporting-system>
154. Shoenfeld, Yehuda, Nancy Agmon-Levin, and Lucija Tomljenovic. 2015. *Vaccines and Autoimmunity*. Wiley-Blackwell.
155. Exley PhD, Christopher. 2020. *Imagine You Are an Aluminum Atom: Discussions with Mr. Aluminum*. Skyhorse Publishing.
156. Zatta, P. F., and A. C. Alfrey. 1997. *Aluminium Toxicity in Infants' Health and Disease*. World Scientific Pub Co Inc.

157. Yokel, Robert, and Mari Golub. 1996. *Research Issues in Aluminium Toxicity*. Washington, D.C.: Taylor & Francis.
158. Agency for Toxic Substances and Disease Registry (ATSDR). 2008. "Toxicological Profile for Aluminum." September. <https://www.atsdr.cdc.gov/ToxProfiles/tp22.pdf>
159. Bishop, Nicholas J., Ruth Morley, J. Philip Day, and Alan Lucas. 1997. "Aluminum Neurotoxicity in Preterm Infants Receiving Intravenous-Feeding Solutions." *New England Journal of Medicine* 336: 1557–1562. <https://www.nejm.org/doi/full/10.1056/NEJM199705293362203>
160. Poole, Robert L., Kevin P. Pieroni, Shabnam Gaskari, Tessa K. Dixon, K. T. Park, and John A. Kerner Jr. 2011. "Aluminum in Pediatric Parenteral Nutrition Products: Measured Versus Labeled Content." *The Journal of Pediatric Pharmacology and Therapeutics* 16 (2): 92–97. <https://doi.org/10.5863%2F1551-6776-16.2.92>
161. McFarland, Grant, Elaine La Joie, Paul Thomas, and James Lyons-Weiler. 2020. "Acute Exposure and Chronic Retention of Aluminum in Three Vaccine Schedules and Effects of Genetic and Environmental Variation." *Journal of Trace Elements in Medicine and Biology* 58. <https://doi.org/10.1016/j.jtemb.2019.126444>
162. McFarland, Grant, Elaine La Joie, Paul Thomas, and James Lyons-Weiler. 2020. "Acute Exposure and Chronic Retention of Aluminum in Three Vaccine Schedules and Effects of Genetic and Environmental Variation." *Journal of Trace Elements in Medicine and Biology* 58. <https://doi.org/10.1016/j.jtemb.2019.126444>
163. Lyons-Weiler, James, and Robert Ricketson. 2018. "Reconsideration of the Immunotherapeutic Pediatric Safe Dose Levels of Aluminum." *Journal of Trace Elements in Medicine and Biology* 48: 67–73. <https://doi.org/10.1016/j.jtemb.2018.02.025>
164. Andress, Dennis L., Jeffrey B. Kopp, Norma A. Maloney, Jack W. Coburn, and Donald J. Sherrard. 1987. "Early Deposition of Aluminum in Bone in Diabetic Patients on Hemodialysis." *The New England Journal of Medicine* 316: 292–296. <https://www.nejm.org/doi/full/10.1056/NEJM198702053160602>
165. Priest, N. D., D. Newton, J. P. Day, R. J. Talbot, and A. J. Warner. 1995. "Human Metabolism of Aluminium-26 and Gallium-67 Injected as Citrates." *Human & Experimental Toxicology* 14 (3): 287–293. <https://doi.org/10.1177/096032719501400309>
166. American Academy of Pediatrics, Committee on Nutrition. 1996. "Aluminum Toxicity in Infants and Children." *Pediatrics* 97 (3): 413–416. <https://pubmed.ncbi.nlm.nih.gov/8604282/>
167. Priest, N. D. 2004. "The Biological Behaviour and Bioavailability of Aluminium in Man, with Special Reference to

- Studies Employing Aluminium-26 as a Tracer: Review and Study Update." *Journal of Environmental Monitoring* 6 (5): 376, 392. <https://doi.org/10.1039/b314329p>
168. Poole, Robert L., Kevin P. Pieroni, Shabnam Gaskari, Tessa K. Dixon, K. T. Park, and John A. Kerner Jr. 2011. "Aluminum in Pediatric Parenteral Nutrition Products: Measured Versus Labeled Content." *The Journal of Pediatric Pharmacology and Therapeutics* 16 (2): 92–97. <https://doi.org/10.5863%2F1551-6776-16.2.92>
169. Masson, Jean-Daniel, Guillemette Crépeaux, et al. 2018. "Critical Analysis of Reference Studies on the Toxicokinetics of Aluminum-based Adjuvants." *Journal of Inorganic Biochemistry* 181: 87–95. <https://doi.org/10.1016/j.jinorgbio.2017.12.015>
- 170.
1. "FDA Drug Safety and Availability: Infants at Risk for Aluminum Toxicity with Unapproved Potassium Phosphates Drug Product." fda.gov on Pagefreezer Website archive. February 9. <https://public4.pagefreezer.com/browse/FDA/16-12-2023T13:09/https://www.fda.gov/drugs/drug-safety-and-availability/infants-risk-aluminum-toxicity-unapproved-potassium-phosphates-drug-product>
- 171.
1. "Physicians for Informed Consent Aluminum: Vaccine Risk Statement (VRS)." Physicians for Informed Consent. <https://physiciansforinformedconsent.org/PIC-Aluminum-VRS.pdf>
172. Exley, Christopher. 2004. "The Pro-oxidant Activity of Aluminum." *Free Radical Biology and Medicine* 36 (3): 380–387. <https://doi.org/10.1016/j.freeradbiomed.2003.11.017>
173. Cao, Zheng, Xu Yang, Haiyang Zhang, Haoran Wang, Wanyue Huang, Feibo Xu, Cuicui Zhuang, Xiaoguang Wang, and Yanfei Li. 2016. "Aluminum Chloride Induces Neuroinflammation, Loss of Neuronal Dendritic Spine and Cognition Impairment in Developing Rat." *Chemosphere* 151: 289–295. <https://www.sciencedirect.com/science/article/abs/pii/S00456533516302533>
174. Khafaga, Asmaa Fahmy. 2017. "Exogenous Phosphatidylcholine Supplementation Retrieve Aluminum-induced Toxicity in Male Albino Rats." *Environmental Science and Pollution Research* 24 (18): 15589–15598. <https://doi.org/10.1007/s11356-017-9151-x>
175. Kool, Mirjam, Virginie Pétrilli, Thibaut De Smedt, Aline Rolaz, Hamida Hammad, Menno van Nimwegen, Ingrid M. Bergen, Rosa Castillo, Bart N. Lambrecht, and Jürg Tschopp. 2008. "Cutting

- Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome." *Journal of Immunology* 181 (6): 3755–3759. <https://doi.org/10.4049/jimmunol.181.6.3755>
176. Shaw, Christopher A., and Michael S. Petrik. 2009. "Aluminum Hydroxide Injections Lead to Motor Deficits and Motor Neuron Degeneration." *Journal of Inorganic Biochemistry* 103 (11): 1555–1562. <https://doi.org/10.1016/j.jinorgbio.2009.05.019>
177. Takano, Tomoyuki. 2015. "Role of Microglia in Autism: Recent Advances." *Developmental Neuroscience* 37 (3): 195–202. <https://doi.org/10.1159/000398791>
178. Viezeliene, Dale, et al. 2013. "Selective Induction of IL-6 by Aluminum-induced Oxidative Stress Can Be Prevented by Selenium." *Journal of Trace Elements in Medicine and Biology* 27 (3): 226–229. <https://doi.org/10.1016/j.jtemb.2012.11.001>
179. Alawdi, Shawqi H., et al. 2017. "Neuroprotective Effect of Nanodiamond in Alzheimer's Disease Rat Model: A Pivotal Role for Modulating NF-κB and STAT3 Signaling." *Molecular Neurobiology* 54: 1906–1918. <https://doi.org/10.1007/s12035-016-9762-0>
180. Eikelenboom, Piet, Erik van Exel, Jeroen J. M. Hoozemans, et al. 2010. "Neuroinflammation—An Early Event in Both the History and Pathogenesis of Alzheimer's Disease." *Neurodegenerative Diseases* 7 (1-3): 38–41. <https://doi.org/10.1159/000283480>
181. Lahiri, Debomoy K., Nasser H. Zawia, Nigel H. Greig, et al. 2008. "Early-Life Events May Trigger Biochemical Pathways for Alzheimer's Disease: The 'LEARn' Model." *Biogerontology* 9 (6): 375–379. <https://doi.org/10.1007/s10522-008-9162-6>
182. Bilbo, Staci D., Carina L. Block, Jessica L. Bolton, et al. 2018. "Beyond Infection—Maternal Immune Activation by Environmental Factors, Microglial Development, and Relevance for Autism Spectrum Disorders." *Experimental Neurology* 299 (Part A): 241–251. <https://doi.org/10.1016/j.expneurol.2017.07.002>
183. Parker-Athill, E. Carla, and Jun Tan. 2011. "Maternal Immune Activation and Autism Spectrum Disorder: Interleukin-6 Signaling as a Key Mechanistic Pathway." *Neurosignals* 18 (2): 113–128. <https://doi.org/10.1159/000319828>
184. Butle, S. R., S. P. Gajare, A. P. Deshpande, et al. 2012. "Recent Advances in the Management of Autism: A Review." *Inventi Rapid: Ethnopharmacology* 2012 (4). https://www.researchgate.net/publication/293827739_Recent_Advances_in_the_Management_of_Autism_A_Review
185. Careaga, Milo, Takeshi Murai, and Melissa D. Bauman. 2017. "Maternal Immune Activation and Autism Spectrum Disorder:

- From Rodents to Nonhuman and Human Primates." *Biological Psychiatry* 81 (5): 391–401. <https://doi.org/10.1016/j.biopsych.2016.10.020>
186. Bilbo, Staci D., and Jaclyn M. Schwarz. 2009. "Early-Life Programming of Later-Life Brain and Behavior: A Critical Role for the Immune System." *Frontiers in Behavioral Neuroscience* 3, Article 14: 1–14. <https://doi.org/10.3389/neuro.08.014.2009>
187. Giannotta, G., and N. Giannotta. 2018. "Vaccines and Neuroinflammation." *International Journal of Public Health & Safety* 3 (3): 163. <https://childrenshealthdefense.org/wp-content/uploads/Giannotta-2018-Vaccines-and-neuroinflammation-.pdf>
188. Vargas, Diana L, Caterina Nascimbene, Chitra Krishnan, Andrew W. Zimmerman, and Carlos A. Pardo. 2005. "Neuroglial Activation and Neuroinflammation in the Brain of Patients with Autism." *Annals of Neurology* 57 (1): 67–81. <https://doi.org/10.1002/ana.20315>
189. GlaxoSmithKline (GSK). 2023. "Package Insert: BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)." gskpro.com. October. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Boostrix/pdf/BOOSTRIX.PDF
190. Warfel, Jason M., Lindsey I. Zimmerman, and Tod J. Merkel. 2013. "Acellular Pertussis Vaccines Protect against Disease but Fail to Prevent Infection and Transmission in a Nonhuman Primate Model." *Proceedings of the National Academy of Sciences of the United States of America* 111 (2): 787–792. <https://doi.org/10.1073/pnas.1314688110>
191. Barkoff, Alex-Mikael, Jussi Mertsola, Sophie Guillot, Nicole Guiso, Guy Berbers, and Qiushui He. 2012. "Appearance of Bordetella Pertussis Strains Not Expressing the Vaccine Antigen Pertactin in Finland." *Clinical and Vaccine Immunology* 19 (10): 1703–1704. <https://journals.asm.org/doi/10.1128/cvi.00367-12>
192. Queenan, Anne Marie, Pamela K. Cassidy, and Alan Evangelista. February. "Pertactin-negative Variants of Bordetella Pertussis in the United States." *The New England Journal of Medicine* 368 (6): 583–584. <https://doi.org/10.1056/nejmc1209369>
193. Otsuka, Nao, Hyun-Ja Han, Hiromi Toyozumi-Ajisaka, Yukitsugu Nakamura, Yoshichika Arakawa, Keigo Shibayama, and Kazunari Kamachi. 2012. "Prevalence and Genetic Characterization of Pertactin-Deficient Bordetella Pertussis in Japan." *PLoS One* 7 (2). <https://doi.org/10.1371/journal.pone.0031985>
194. Stefanelli, Paola, Cecilia Fazio, Giorgio Fedele, Fabiana Spensieri, Clara Maria Ausiello, and Paola Mastrantonio. 2009. "A Natural Pertactin Deficient Strain of Bordetella Pertussis Shows

- Improved Entry in Human Monocyte-derived Dendritic Cells." *The New Microbiologica* 32 (2): 159–
166. <https://pubmed.ncbi.nlm.nih.gov/19579693/>
195. Zheteyeva, Yenlik A., Pedro L. Moro, Naomi K. Tepper, Sonja A. Rasmussen, Faith E. Barash, Natalia V. Revzina, Dmitry Kissin, et al. 2012. "Adverse Event Reports after Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines in Pregnant Women." *American Journal of Obstetrics & Gynecology* 207 (1). <https://doi.org/10.1016/j.ajog.2012.05.006>
196. Kharbanda, Elyse O., et al. 2014. "Evaluation of the Association of Maternal Pertussis Vaccination with Obstetric Events and Birth Outcomes." *JAMA* 312 (18): 1897–
1904. <https://doi.org/10.1001/jama.2014.14825>
197. Layton, Bradley J., et al. 2017. "Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events." *Vaccine* 35 (33): 4072–4078. <https://doi.org/10.1016/j.vaccine.2017.06.071>
198. DeSilva, Malini, et al. 2017. "Maternal Tdap Vaccination and Risk of Infant Morbidity." *Vaccine* 35 (29): 3655–
3660. <https://doi.org/10.1016/j.vaccine.2017.05.041>
199. Baxter, Roger, Joan Bartlett, Ali Rowhani-Rahbar, Bruce Fireman, and Nicola P. Klein. 2013. "Effectiveness of Pertussis Vaccines for Adolescents and Adults: Case-Control Study." *BMJ* 347. <https://www.bmj.com/content/347/bmj.f4249>
200. Koepke, Ruth, Jens C. Eickhoff, Roman A. Ayele, et al. 2014. "Estimating the Effectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) for Preventing Pertussis: Evidence of Rapidly Waning Immunity and Difference in Effectiveness by Tdap Brand." *The Journal of Infectious Diseases* 210 (6): 942–
953. <https://doi.org/10.1093/infdis/jiu322>
201. Witt, Maxwell A., Paul H. Katz, and David J. Witt. 2012. "Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Preadolescents in a North American Outbreak." *Clinical Infectious Diseases* 54 (12): 1730–
1735. <https://doi.org/10.1093/cid/cis287>
202. Griffin, R. Morgan. 2022. "What Are Your Odds of Getting the Flu?" WebMD.com, November
19. <https://www.webmd.com/cold-and-flu/flu-statistics>
203. Centers for Disease Control and Prevention. 2023. "Influenza (Flu) Past Seasons' Vaccine Effectiveness Estimates." cdc.gov. June
2. <https://www.cdc.gov/flu/vaccineswork/past-seasons-estimates.html>
204. Rikin, S., H. Jia, C.Y. Vargas, Y. Castellanos de Belliard, C. Reed, P. LaRussa, E. L. Larson, L. Saiman, and M. S. Stockwell. 2018. "Assessment of Temporally-related Acute Respiratory Illness following Influenza Vaccination." *Vaccine* 36 (15): 1958–
1964. <https://doi.org/10.1016%2Fj.vaccine.2018.02.105>

205. Dierig, A., L. G. Heron, S. B. Lambert, J. K. Yin, J. Leask, M. Y. Chow, T. P. Sloots, M. D. Nissen, I. Ridda, and R. Booy. 2014. "Epidemiology of Respiratory Viral Infections in Children Enrolled in a Study of Influenza Vaccine Effectiveness." *Influenza and Other Respiratory Viruses* 8 (3): 293–301. <https://doi.org/10.1111/irv.12229>
206. Rikin, S., H. Jia, C.Y. Vargas, Y. Castellanos de Belliard, C. Reed, P. LaRussa, E. L. Larson, L. Saiman, and M. S. Stockwell. 2018. "Assessment of Temporally-related Acute Respiratory Illness Following Influenza Vaccination." *Vaccine* 36 (15): 1958–1964. <https://doi.org/10.1016%2Fj.vaccine.2018.02.105>
207. Centers for Disease Control and Prevention. 2022. "Selecting Viruses for the Seasonal Influenza Vaccine." [cdc.gov](https://www.cdc.gov/flu/prevent/vaccine-selection.htm). November. <https://www.cdc.gov/flu/prevent/vaccine-selection.htm>
208. Demicheli, V., T. Jefferson, E. Ferroni, A Rivetti, and C. Di Pietrantonj. 2018. "Vaccines for Preventing Influenza in Healthy Adults." *Cochrane Database of Systematic Reviews* 2 (2). <https://doi.org/10.1002/14651858.cd001269.pub6>
209. Jefferson, T., C. Di Pietrantonj, A. Rivetti, G. A. Bawazeer, L. A. Al-Ansary, and E. Ferroni. 2010. "Vaccines for Preventing Influenza in Healthy Adults." *Cochrane Database of Systematic Reviews* (7). <https://doi.org/10.1002/14651858.CD001269.pub4>
210. Ohmit, S. E., J. G. Petrie, R. E. Malosh, B. J. Cowling, M. G. Thompson, D. K. Shay, and A. S. Monto. 2013. "Influenza Vaccine Effectiveness in the Community and the Household." *Clinical Infectious Diseases* 56 (10): 1363–1369. <https://doi.org/10.1093%2Fcid%2Fcid060>
- 211.
1. "Physicians for Informed Consent Vaccines and Immunocompromised Schoolchildren: Risk Group Information Statement (RGIS)." Physicians for Informed Consent. July. <https://physiciansforinformedconsent.org/immunocompromised-schoolchildren/rgis/>
212. Goldman, G. S. 2013. "Comparison of VAERS Fetal-loss Reports During Three Consecutive Influenza Seasons: Was There a Synergistic Fetal Toxicity Associated with the Two-vaccine 2009/2010 Season?" *Human & Experimental Toxicology* 32 (5): 464–475. <https://doi.org/10.1177/0960327112455067>
213. Donahue, James G., Burney A. Kieke, Jennifer P. King, Frank DeStefano, Maria A. Mascola, et al. 2017. "Association of Spontaneous Abortion with Receipt of Inactivated Influenza Vaccine Containing H1N1pdm09 in 2010-11 and 2011-12." *Vaccine* 35 (40): 5314–5322. <https://doi.org/10.1016/j.vaccine.2017.06.069>
214. Zerbo, Ousseny, Yingge Qian, Cathleen Yoshida, Bruce Fireman, Nicola P. Klein, and Lisa A. Croen. 2017. "Association

- Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder." *JAMA Pediatrics* 171 (1). <https://doi.org/10.1001/jamapediatrics.2016.3609>
215. Christian, Lisa M., et al. 2011. "Inflammatory Responses to Trivalent Influenza Virus Vaccine among Pregnant Women." *Vaccine* 29 (48): 8982–8987. <https://doi.org/10.1016/j.vaccine.2011.09.039>
216. Blaylock, R. L. Summer 2004. "Chronic Microglial Activation and Excitotoxicity Secondary to Excessive Immune Stimulation: Possible Factors in Gulf War Syndrome and Autism." *Journal of American Physicians and Surgeons* 9 (2): 46–51. <https://www.jpands.org/vol9no2/blaylock.pdf>
217. Centers for Disease Control and Prevention. n.d. "CDC Wonder: About Underlying Cause of Death, 1999–2020." [cdc.gov. https://web.archive.org/web/20240223043502/https://wonder.cdc.gov/ucd-icd10.html](https://web.archive.org/web/20240223043502/https://wonder.cdc.gov/ucd-icd10.html)
218. Harper, S. A., K. Fukuda, T. M. Uyeki, N. J. Cox, C. B. Bridges, and Centers for Disease Control and Prevention (CDC) A. 2004. "Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)." *MMWR: Recommendations and Reports* 53 (RR-6): 1–40. <https://pubmed.ncbi.nlm.nih.gov/15163927/>
219. Joshi, A. Y., V. N. Iyer, et al. 2012. "Effectiveness of Trivalent Inactivated Influenza Vaccine in Influenza-related Hospitalization in Children: A Case-Control Study." *Allergy and Asthma Proceedings* 33 (2). <https://doi.org/10.2500/aap.2012.33.3513>
220. Jain, Samhita, Rebecca J. Baer, Charles E. McCulloch, et al. 2021. "Association of Maternal Immune Activation during Pregnancy and Neurologic Outcomes in Offspring." *The Journal of Pediatrics* 238: 87–93. <https://doi.org/10.1016/j.jpeds.2021.04.069>
221. Cowling, Benjamin J., Vicky J. Fang, Hiroshi Nishiura, et al. 2012. "Increased Risk of Noninfluenza Respiratory Virus Infections Associated with Receipt of Inactivated Influenza Vaccine." *Clinical Infectious Diseases* 54 (12): 1778–1783. <https://doi.org/10.1093/cid/cis307>
222. Centers for Disease Control and Prevention. 2022. "Symptoms of COVID-19." [cdc.gov. October 26. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
223. Perez, Jean Claude, Claire Moret-Chalmin, and Luc Montagnier. 2022. "Towards the Emergence of a New Form of the Neurodegenerative Creutzfeldt-Jakob Disease: Twenty-Six Cases of CJD Declared a Few Days after a COVID-19 'Vaccine' Jab (Version V4)." Zenodo. <https://doi.org/10.5281/zenodo.6641998>
224. DeSilva, Malini, et al. 2022. "Evaluation of Acute Adverse

- Events after Covid-19 Vaccination during Pregnancy." *The New England Journal of Medicine* 387 (2): 187–189. <https://doi.org/10.1056/NEJMc2205276>
225. Dick, Aharon, et al. 2022. "Safety of SARS-CoV-2 Vaccination during Pregnancy—Obstetric Outcomes from a Large Cohort Study." *BMC Pregnancy Childbirth* 22 (166). <https://doi.org/10.1186/s12884-022-04505-5>
226. Kennedy Jr., Robert F., and Brian Hooker. 2023. *Vax-Unvax: Let the Science Speak*. Skyhorse Publishing.
227. Montano, Diego. 2022. "Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States." *Frontiers in Public Health, Section: Infectious Diseases—Surveillance, Prevention and Treatment* 9. <https://doi.org/10.3389/fpubh.2021.756633>
228. Aaby, Peter, Christine S. Benn, Katie L. Flanagan, Sabra L. Klein, Tobias R. Kollmann, David J. Lynn, and Frank Shann. 2020. "The Non-specific and Sex-differential Effects of Vaccines." *Nature Reviews Immunology* 20: 464–470. <https://www.nature.com/articles/s41577-020-0338-x>
229. Leeyaphan, Charussri, et al. 2023. "Herpes Zoster after COVID-19 Infection or Vaccination: A Prospective Cohort Study in a Tertiary Dermatology Clinic." *Dermatology Research and Practice* 2023: 8 pages. <https://doi.org/10.1155/2023/2206498>
230. Berild, Jacob D., Vilde B. Larsen, Emilia M. Thiesson, et al. 2022. "Analysis of Thromboembolic and Thrombocytopenic Events after the AZD1222, BNT162b2, and mRNA-1273 COVID-19 Vaccines in 3 Nordic Countries." *JAMA Network Open* 5 (6). <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793348>
231. Mevorach, Dror, et al. 2021. "Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel." *The New England Journal of Medicine* 385: 2140–2149. <https://doi.org/10.1056/NEJMoa2109730>
232. Massari, Marco, et al. 2022. "Postmarketing Active Surveillance of Myocarditis and Pericarditis following Vaccination with COVID-19 mRNA Vaccines in Persons Aged 12 to 39 Years in Italy: A Multi-database, Self-controlled Case Series Study." *PLoS Medicine* 19 (7). <https://doi.org/10.1371/journal.pmed.1004056>
233. Simone, Anthony, et al. 2022. "Acute Myocarditis following a Third Dose of COVID-19 mRNA Vaccination in Adults." *International Journal of Cardiology* 65: 41–43. <https://doi.org/10.1016/j.ijcard.2022.07.031>
234. Patone, Martina, et al. 2022. "Risk of Myocarditis after Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection

- by Age and Sex." *Circulation* 146
(10). <https://doi.org/10.1161/CIRCULATIONAHA.122.059970>
235. Karlstad, Øystein, et al. 2022. "SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents." *JAMA Cardiology* 7 (6): 600–612. <https://doi.org/10.1001/jamacardio.2022.0583>
236. Lai, Daoyuan, et al. 2022. "Risk of Myocarditis after Two Doses of COVID-19 mRNA Vaccines in the US, 2020–2022: A Self-controlled Case Series Study [PREPRINT (Version 1)]." *Research Square*. <https://doi.org/10.21203/rs.3.rs-1741089/v1>
237. Hulscher, Nicholas, Michael Cook, Raphael Stricker, and Peter A. McCullough. 2024. "Excess Cardiopulmonary Arrest and Mortality after COVID-19 Vaccination in King County, Washington." *Preprints*, 2024051665. <https://doi.org/10.20944/preprints202405.1665.v1>
238. Centers for Disease Control and Prevention. 2021. "Vaccines and Immunizations: Definition of Terms." cdc.gov. September 1. <https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm>
239. Centers for Disease Control and Prevention. 2021. "Chapter 10: Hepatitis B." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 14th ed. (The Pink Book)*, edited by Penina Haber and Sarah Schillie. Washington, D.C.: Public Health Foundation. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf>
240. Magno, Hector, and Beatrice Golomb. 2020. "Measuring the Benefits of Mass Vaccination Programs in the United States." *Vaccines* 8 (4): 561. <https://doi.org/10.3390%2Fvaccines8040561>
241. Roberts, Henry, Deanna Kruszon-Moran, Kathleen N. Ly, Elizabeth Hughes, Kashif Iqbal, Ruth B. Jiles, and Scott D. Holmberg. 2016. "Prevalence of Chronic Hepatitis B Virus (HBV) Infection in U.S. Households: National Health and Nutrition Examination Survey (NHANES), 1988–2012." *Hepatology* 63 (2): 388–397. <https://doi.org/10.1002/hep.28109>
242. Gallagher, Carolyn M., and Melody S. Goodman. 2010. "Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997–2002." *Journal of Toxicology and Environmental Health, Part A* 73 (24): 1665–1677. <https://doi.org/10.1080/15287394.2010.519317>
243. Fisher, Monica A., and Stephen A. Eklund. 1999. "Hepatitis B Vaccine and Liver Problems in U.S. Children Less Than 6 Years Old, 1993 and 1994." *Epidemiology* 10 (3): 337–339. <https://pubmed.ncbi.nlm.nih.gov/10230847/>
244. Hernán, Miguel A., Susan S. Jick, Michael J. Olek, and Hershel Jick. 2004. "Recombinant Hepatitis B Vaccine and the Risk

- of Multiple Sclerosis." *Neurology* 63 (5): 838–842. <https://doi.org/10.1212/01.WNL.0000138433.61870.82>
245. Classen, David C., and John B. Classen. 1997. "Hypothesis: The Timing of Pediatric Immunization and the Risk of Insulin-Dependent Diabetes Mellitus." *Infectious Diseases in Clinical Practice* 6 (7): 449–454. https://journals.lww.com/infectedis/citation/1997/06070/the_timing_of_pediatric_immunization_and_the_risk.7.aspx
246. Yon, Dong Keong, et al. 2018. "Hepatitis B Immunogenicity after a Primary Vaccination Course Associated with Childhood Asthma, Allergic Rhinitis, and Allergen Sensitization." *Pediatric Allergy and Immunology (PAI)* 29 (2): 221–224. <https://doi.org/10.1111/pai.12850>
247. Puliyeel, J, P. Naik, A. Puliyeel, K. Agarwal, V. Lal, N. Kansal, D. Nandan, et al. 2018. "Evaluation of the Protection Provided by Hepatitis B Vaccination in India." *Indian Journal of Pediatrics* 85 (7): 510–516. <https://doi.org/10.1007/s12098-017-2601-0>
248. Cornelissen, M., R. von Kries, P. Loughnan, and G. Schubiger. 1997. "Prevention of Vitamin K Deficiency Bleeding: Efficacy of Different Multiple Oral Dose Schedules of Vitamin K." *European Journal of Pediatrics* 156 (2): 126–130. <https://doi.org/10.1007/s004310050570>
249. Links to results of three clinical trials on ClinicalTrials.gov: [NCT03979313](https://clinicaltrials.gov/ct2/show/study/NCT03979313) | [NCT02878330](https://clinicaltrials.gov/ct2/show/study/NCT02878330) | [NCT03959488](https://clinicaltrials.gov/ct2/show/study/NCT03959488)
250. AstraZeneca. 2023. "Package Insert: BEYFORTUS (nirsevimab-alip) injection, for intramuscular use Initial U.S. Approval: 2023." [fda.gov. July. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf)
251. Prill, Mila M., Gayle E. Langley, Amber Winn, and Susan I. Gerber. 2021. "Respiratory Syncytial Virus-associated Deaths in the United States according to Death Certificate, 2005 to 2016." *Health Science Reports* 4 (4). <https://doi.org/10.1002%2Fhshr.2.428>
252. Centers for Disease Control and Prevention. 2023. "CDC Recommends a Powerful New Tool to Protect Infants from the Leading Cause of Hospitalization." [cdc.gov. August 3. https://www.cdc.gov/media/releases/2023/p-0803-new-tool-prevent-infant-hospitalization-.html](https://www.cdc.gov/media/releases/2023/p-0803-new-tool-prevent-infant-hospitalization-.html)
253. Hedley K et al. "Alterations in Brainstem Respiratory Centers following Peripheral Inflammation: A systematic review." *Journal of Neuroimmunology* 2022;369:577903. Hoogland ICM et al. "Systemic Inflammation and Microglial Activation: Systematic review of Animal Experiments." *Journal of Neuroinflammation* 2015;12, article number 114.
254. Miller, Neil Z. 2021. "Vaccines and Sudden Infant Death: An

- Analysis of the VAERS Database 1990–2019 and Review of the Medical Literature." *Toxicology Reports* 8: 1324–1335. <https://doi.org/10.1016/j.toxrep.2021.06.020>
255. Miller, Neil Z. 2021. "Vaccines and Sudden Infant Death: An Analysis of the VAERS Database 1990–2019 and Review of the Medical Literature." *Toxicology Reports* 8: 1324–1335. <https://doi.org/10.1016/j.toxrep.2021.06.020>
- 256.
1. "GlaxoSmithKline Confidential Clinical Study Final Report: Study 113808 (ROTA-075)." October 29. <https://s3.amazonaws.com/ctr-gsk-7381/113808/5056b56b-5311-466e-9f63-d1b647b37b89/321842cb-a46c-4e78-9154-e1773829baa7/gsk-113808-clinical-study-report-redact-v1.pdf>
257. Lazarus, Ross. 2010. *Electronic Support for Public Health—Vaccine Adverse Event Reporting System (ESP:VAERS)*. Grant Final Report, The Agency for Healthcare Research and Quality (AHRQ) U.S. Department of Health and Human Services, Boston: Harvard Pilgrim Health Care, Inc. <https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-public-health-vaccine-adverse-event-reporting-system>
258. Centers for Disease Control and Prevention. Division of Reproductive Health. 2023. "Maternal and Infant Health: Infant Mortality." cdc.gov. September 13. <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/infantmortality.htm>
259. Ram M, Shoenfeld Y. "Hepatitis B: Infection, Vaccination and Autoimmunity." 2008; *The Israel Medical Association Journal* 10: 61–64.
- 260.
1. "Judicial Notice: Numerical Risk Comparison of Non-vaccination Versus Vaccination." vaxcheckers.org. September. <https://vaxcheckers.org/wp-content/uploads/2021/09/PRJN4.pdf>
261. Centers for Disease Control and Prevention. 2021. "Chapter 7 Diphtheria." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 14th ed. (The Pink Book)*, edited by Anna M. Acosta, Pedro L. Moro, Susan Hariri and Tejpratap S.P. Tiwari. Washington, D.C.: Public Health Foundation. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf>
262. Humphries MD, Suzanne, and Roman Bystrianyk. 2013. *Dissolving Illusions: Disease, Vaccines, and the Forgotten History*. CreateSpace Independent Publishing Platform.

263. College of Physicians of Philadelphia. 2022. "History of Diphtheria." History of Vaccines. April 9. <https://historyofvaccines.org/history/diphtheria/overview>
264. Centers for Disease Control and Prevention. 2015. "Chapter 7: Diphtheria." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 13th ed. (The Pink Book)*, edited by Jennifer Hamborsky, Andrew Kroger and Charles Wolfe, 107–118. Washington, D.C.: Public Health Foundation.
265. Centers for Disease Control and Prevention. n.d. "Morbidity and Mortality Weekly Report (MMWR): Summary of Notifiable Infectious Diseases." cdc.gov. Accessed April 30, 2024. https://www.cdc.gov/mmwr/mmwr_nd/index.html
266. Centers for Disease Control and Prevention. 1996. "Chapter 16: Tetanus." In *Manual for the Surveillance of Vaccine-Preventable Diseases*, by Amy Blain and Tejpratap S. P. Tiwari. Atlanta, GA: National Center for Immunization and Respiratory Diseases. <https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html>
267. Long, G. H., A. T. Karanikas, E. T. Harvill, A. F. Read, and P. J. Hudson. 2010. "Acellular Pertussis Vaccination Facilitates Bordetella Parapertussis Infection in a Rodent Model of Bordetellosis." *Proceedings of the Royal Society of Biological Sciences* 277 (1690): 2017–2025. <https://doi.org/10.1098%2Frspsb.2010.0010>
268. Ma, L., A. Caulfield, K. K. Dewan, and E. T. Harvill. 2021. "Pertactin-Deficient Bordetella Pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis." *Emerging Infectious Diseases* 27 (6): 1561–1566. <https://doi.org/10.3201/eid2706.203850>
269. Grove, Robert D., and Alice M. Hetzel. 1968. "Vital Statistics Rates in the United States: 1940–1960." cdc.gov National Center for Health Statistics. https://www.cdc.gov/nchs/data/vsus/vsrates1940_60.pdf
270. Centers for Disease Control and Prevention. 2022. "Surveillance & Reporting: Pertussis Cases by Year (1922–2021)." cdc.gov. August 4. <https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html>
271. 1. "Judicial Notice: Numerical Risk Comparison of Non-vaccination Versus Vaccination." vaxcheckers.org. September. <https://vaxcheckers.org/wp-content/uploads/2021/09/PRJN4.pdf>
272. Humphries MD, Suzanne, and Roman Bystryanyk. 2013. *Dissolving Illusions: Disease, Vaccines, and the Forgotten History*. CreateSpace Independent Publishing Platform.
273. Mehndiratta, M. M., P. Mehndiratta, and Pande R. 2014.

- "Poliomyelitis: Historical Facts, Epidemiology, and Current Challenges in Eradication." *Neurohospitalist* 4 (4): 223–229. <https://doi.org/10.1177/1941874414533352>
274. Centers for Disease Control and Prevention. 2009. *Epidemiology and Prevention of Vaccine-Preventable Diseases 11th ed. (The Pink Book)*. Edited by W. Atkinson, S. Wolfe, J. Hamborsky and L. McIntyre. Washington, D.C.: Public Health Foundation.
275. Centers for Disease Control and Prevention. 2021. "Chapter 18 Poliomyelitis." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 14th ed. (The Pink Book)*, edited by E. Hall, A. P. Wodi, J. Hamborsky, V. Morelli and S. Schillie, 276. Washington, D.C.: Public Health Foundation. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/polio.pdf>
276. Centers for Disease Control and Prevention. 2023. "What is Polio?" cdc.gov. January 9. <https://www.cdc.gov/polio/what-is-polio/index.htm>
277. Magno, Hector, and Beatrice Golomb. 2020. "Measuring the Benefits of Mass Vaccination Programs in the United States." *Vaccines* 8 (4): 561. <https://doi.org/10.3390%2Fvaccines8040561>
- 278.
1. "Physicians for Informed Consent Polio: Vaccine Risk Statement (VRS)." Physicians for Informed Consent. August. <https://physiciansforinformedconsent.org/polio-vrs/>
279. Magno, Hector, and Beatrice Golomb. 2020. "Measuring the Benefits of Mass Vaccination Programs in the United States." *Vaccines* 8 (4): 561. <https://doi.org/10.3390%2Fvaccines8040561>
280. Centers for Disease Control and Prevention. 2009. *Epidemiology and Prevention of Vaccine-Preventable Diseases 11th ed. (The Pink Book)*. Edited by W. Atkinson, S. Wolfe, J. Hamborsky and L. McIntyre. Washington, D.C.: Public Health Foundation.
281. Centers for Disease Control and Prevention. 2021. "Chapter 18 Poliomyelitis." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 14th ed. (The Pink Book)*, edited by E. Hall, A. P. Wodi, J. Hamborsky, V. Morelli and S. Schillie, 276. Washington, D.C.: Public Health Foundation. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/polio.pdf>
282. Centers for Disease Control and Prevention. 2023. "What is Polio?" cdc.gov. January 9. <https://www.cdc.gov/polio/what-is-polio/index.htm>

283. Sanofi Pasteur. 2022. "Package Insert: IPOL®, Poliovirus Vaccine Inactivated." fda.gov. May. <https://www.fda.gov/media/75695/download>
- 284.
1. "Physicians for Informed Consent Polio: Vaccine Risk Statement (VRS)." Physicians for Informed Consent. August. <https://physiciansforinformedconsent.org/polio-vrs/>
- 285.
1. "VAERS Data." Vaccine Adverse Event Reporting System (VAERS) on HHS.gov. <https://vaers.hhs.gov/data.html>
286. Bisgard, Kristine M., Annie S. Kao, John Leake, Peter M. Strebel, Bradley A. Perkins, and Melinda Wharton. 1998. "Haemophilus Influenzae Invasive Disease in the United States, 1994–1995: Near Disappearance of a Vaccine-Preventable Childhood Disease." *Emerging Infectious Diseases* 4 (2): 229–237. <https://pubmed.ncbi.nlm.nih.gov/9621193/>
287. Bisgard, Kristine M., Annie S. Kao, John Leake, Peter M. Strebel, Bradley A. Perkins, and Melinda Wharton. 1998. "Haemophilus Influenzae Invasive Disease in the United States, 1994–1995: Near Disappearance of a Vaccine-Preventable Childhood Disease." *Emerging Infectious Diseases* 4 (2): 229–237. <https://pubmed.ncbi.nlm.nih.gov/9621193/>
288. Bruce, Michael G., Tammy Zulz, Carolyn DeByle, Ros Singleton, Debby Hurlburt, Dana Bruden, Karen Rudolph, Thomas Hennessy, Joseph Klejka, and Jay D. Wenger. 2013. "Haemophilus influenzae Serotype A Invasive Disease, Alaska, USA, 1983–2011." *Emerging Infectious Diseases* 19 (6): 932–937. <https://pubmed.ncbi.nlm.nih.gov/23735653/>
289. Ribeiro, G. S., J. N. Reis, S. M. Cordeiro, J. B. Lima, E. L. Gouveia, M. Petersen, K. Salgado, et al. 2003. "Prevention of Haemophilus Influenzae Type B (Hib) Meningitis and Emergence of Serotype Replacement with Type A Strains after Introduction of Hib Immunization in Brazil." *The Journal of Infectious Diseases* 187 (1): 109–116. <https://doi.org/10.1086/345863>
290. Adam, H. J., S. E. Richardson, F. B. Jamieson, P. Rawte, D. E. Low, and D. N. Fisman. 2010. "Changing Epidemiology of Invasive Haemophilus Influenzae in Ontario, Canada: Evidence for Herd Effects and Strain Replacement Due to Hib Vaccination." *Vaccine* 28 (24): 4073–4078. <https://www.sciencedirect.com/science/article/abs/pii/S0264410X10004755>
291. Sadeghi-Aval, Pouya, Raymond S.W. Tsang, Frances B. Jamieson, and Marina Ulanova. 2013. "Emergence of Non-Serotype b Encapsulated Haemophilus Influenzae as a Cause of Pediatric Meningitis in Northwestern Ontario." *Canadian Journal of Infectious*

- Diseases and Medical Microbiology* 24 (1): 13–16. <https://doi.org/10.1155%2F2013%2F828730>
292. Classen, John B., and David C. Classen. 2002. "Clustering of Cases of Insulin Dependent Diabetes (IDDM) Occurring Three Years after Hemophilus Influenza B (HiB) Immunization Support Causal Relationship between Immunization and IDDM." *Autoimmunity* 35 (4): 247–253. <https://www.tandfonline.com/doi/abs/10.1080/08916930290028175>
293. Wahlberg, J., J. Fredriksson, O. Vaarala, J. Ludvigsson, and Abis Study Group. 2003. "Vaccinations May Induce Diabetes-Related Autoantibodies in One-Year-Old Children." *Annals of the New York Academy of Sciences* 1005 (1): 404–408. <https://doi.org/10.1196/annals.1288.068>
294. Classen, John B., and David C. Classen. 1999. "Public Should Be Told That Vaccines May Have Long Term Adverse Effects." *BMJ* 318 (7177): 193. <https://www.bmj.com/content/318/7177/193.1>
295. Classen, John B., and David C. Classen. 1999. "Association between Type 1 Diabetes and Hib Vaccine. Causal Relation is Likely." *BMJ* 319 (7217): 1133. <https://www.bmj.com/content/319/7217/1133.1>
296. 1. "VAERS Data." Vaccine Adverse Event Reporting System (VAERS) on HHS.gov. <https://vaers.hhs.gov/data.html>
297. Centers for Disease Control and Prevention. 2021. "Vaccine Information Statement: Rotavirus Vaccine—What You Need to Know." cdc.gov. October 15. <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rotavirus.pdf>
298. Ruiz-Palacios, Guillermo M., I. Pérez-Schael, F. Velázquez, H. Abate, Human Rotavirus Vaccine Study Group, et al. 2006. "Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis." *The New England Journal of Medicine* 354 (1): 11–22. <https://doi.org/10.1056/nejmoa052434>
299. Vesikari, Timo, David O. Matson, Penelope Dennehy, Pierre Van Damme, Mathuram Santosham, Zoe Rodriguez, et al., and for the Rotavirus Efficacy and Safety Trial (REST). 2006. "Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine." *The New England Journal of Medicine* 354: 23–33. <https://doi.org/10.1056/NEJMoa052664>
300. Hooker, Brian, J. Kern, D. Geier, B. Haley, L. Sykes, P King, and M. Geier. 2014. "Methodological Issues and Evidence of Malfeasance in Research Purporting to Show Thimerosal in Vaccines Is Safe." *BioMed Research*

- International*. <https://doi.org/10.1155%2F2014%2F247218>
301. Sharpe, Martyn A., Andrew D. Livingston, and David S. Baskin. 2012. "Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA." *Journal of Toxicology* 2012. <https://doi.org/10.1155/2012/373678>
 302. Barregard, Lars, Dinko Rekić, Milena Horvat, Lisa Elmberg, Thomas Lundh, and Olof Zachrisson. 2011. "Toxicokinetics of Mercury after Long-term Repeated Exposure to Thimerosal-containing Vaccine." *Toxicological Sciences* 120 (2): 499–506. <https://academic.oup.com/toxsci/article/120/2/499/1670799>
 303. Bragadin, Marcantonio, Daniele Marton, Sabrina Manente, Mario Grasso, and Antonio Toninello. 2002. "Methylmercury Induces the Opening of the Permeability Transition Pore in Rat Liver Mitochondria." *Journal of Inorganic Biochemistry* 89 (1-2): 159–162. <https://pubmed.ncbi.nlm.nih.gov/11931977/>
 304. Canty, A. J., P. W. Moors, and G. B. Deacon. 1984. "Octanol/Water Partition Coefficients as a Model System for Assessing Antidotes for Methylmercury (II) Poisoning, and for Studying Mercurials with Medicinal Applications." *Journal of Inorganic Biochemistry* 22 (1): 65–72. <https://www.sciencedirect.com/science/article/abs/pii/0162013484850643>
 305. Yin, Zhaobao, Eunsook Lee, Mingwei Ni, Haiyan Jiang, Dejan Milatovic, Lu Rongzhu, Marcelo Farina, Joao B.T. Rocha, and Michael Aschner. 2011. "Methylmercury-induced Alterations in Astrocyte Functions Are Attenuated by Ebsele." *NeuroToxicology* 32 (3): 291–299. <https://doi.org/10.1016/j.neuro.2011.01.004>
 306. Kirby, David. 2006. *Evidence of Harm: Mercury in Vaccines and the Autism Epidemic: A Medical Controversy*. St. Martin's Griffin.
 307. Centers for Disease Control and Prevention. 2024. "CDC Seasonal Flu Vaccine Effectiveness Studies." cdc.gov. February 29. <https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm>
 308. Bodewes, Rogier, Joost H.C.M. Kreijtz, and Guus F. Rimmelzwaan. 2009. "Yearly Influenza Vaccinations: A Double-edged Sword?" *The Lancet Infectious Diseases* 9 (12): 784–788. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(09\)70263-4/abstract70263-4/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(09)70263-4/abstract70263-4/abstract)
 309. Donahue, James G., Burney A. Kieke, Jennifer P. King, Frank DeStefano, Maria A. Mascola, et al. 2017. "Association of Spontaneous Abortion with Receipt of Inactivated Influenza Vaccine Containing H1N1pdm09 in 2010-11 and 2011-12." *Vaccine* 35 (40): 5314–5322. <https://doi.org/10.1016/j.vaccine.2017.06.069>

310. Sencer, David J., and J. Donald Millar. 2006. "Reflections on the 1976 Swine Flu Vaccination Program." *Emerging Infectious Diseases* 12 (1): 29–33. <https://doi.org/10.3201%2F1201.051007>
311. 1. "VAERS Data." Vaccine Adverse Event Reporting System (VAERS) on HHS.gov. <https://vaers.hhs.gov/data.html>
312. 1. "Institute for Vaccine Safety: Package Inserts and Manufacturers for Some US Licensed Vaccines and Immunoglobulins." October 27. <https://www.vaccinesafety.edu/package-inserts-and-manufacturers-for-some-us-licensed-vaccines-and-immunoglobulins/>
313. Hayward, Andrew C., Ellen B. Fragaszy, Alison Bermingham, Lili Wang, Andrew Copas, et al. 2014. "Comparative Community Burden and Severity of Seasonal and Pandemic Influenza: Results of the Flu Watch Cohort Study." *The Lancet Respiratory Medicine* 2 (6): 445–454. [https://doi.org/10.1016/S2213-2600\(14\)70034-7](https://doi.org/10.1016/S2213-2600(14)70034-7)
314. Centers for Disease Control and Prevention. "Pneumonia and Influenza Mortality Surveillance from the National Center for Health Statistics Mortality Surveillance System." cdc.gov. Accessed 2024. <https://gis.cdc.gov/grasp/fluview/mortality.html>
315. 1. "SARS CoV Patent Corpus Literature Review." M-CAM International LLC. April. https://www.m-cam.com/wp-content/uploads/2020/04/20200403_SARS_CoV_Patent_Corpus_Lit_Review.pdf
316. Mansanguan, S., P. Charunwatthana, et al. 2022. "Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents." *Tropical Medicine and Infectious Disease* 7 (8): 196. <https://doi.org/10.3390/tropicalmed7080196>
317. Seneff, Stephanie, Greg Nigh, Anthony M. Kyriakopoulos, and Peter A. McCullough. 2022. "Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The Role of G-quadruplexes, Exosomes, and MicroRNAs." *Food and Chemical Toxicology* 164. <https://doi.org/10.1016/j.fct.2022.113008>
318. Polykretis, Panagis, Alberto Donzelli, Janci C. Lindsay, David Wiseman, et al. 2023. "Autoimmune Inflammatory Reactions Triggered by the COVID-19 Genetic Vaccines in Terminally Differentiated Tissues." *Autoimmunity* 56 (1). <https://doi.org/10.1080/08916934.2023.2259123>
319. Rapkiewiczza, Amy V., Xingchen Mai, Steven E. Carsons, Stefania Pittalugac, et al. 2020. "Megakaryocytes and Platelet-fibrin Thrombi Characterize Multi-Organ Thrombosis at Autopsy in

- COVID-19: A Case Series." *EClinicalMedicine* 24. <https://doi.org/10.1016%2Fj.eclinm.2020.100434>
320. Kory, Pierre. 2023. "Our Reply to the American Board of Internal Medicine." *Pierre Kory's Medical Musings* on Substack. August 5. <https://pierrekorymedicalmusings.com/p/our-reply-to-the-american-board-of>
321. King, William W., et al. 2021. "Myocarditis Following mRNA Vaccination Against SARS-CoV-2, a Case Series." *American Heart Journal Plus: Cardiology Research and Practice* 8. <https://doi.org/10.1016/j.ahjo.2021.100042>
322. Montgomery, Jay, Margaret Ryan, Renata Engler, et al. 2021. "Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military." *JAMA Cardiology* 6 (10): 1202–1206. <https://doi.org/10.1001/jamacardio.2021.2833>
323. Dionne, Audrey, Francesca Sperotto, Stephanie Chamberlain, et al. 2021. "Association of Myocarditis with BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children." *JAMA Cardiology* 6 (12): 1446–1450. <https://doi.org/10.1001/jamacardio.2021.3471>
324. Marshall MD, Mayme, Ian D. Ferguson, et al. 2021. "Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination." *Pediatrics* 148 (3). <https://doi.org/10.1542/peds.2021-052478>
325. Luk MD, Adriana, et al. 2021. "Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers." *Canadian Journal of Cardiology* 37 (10): 1629–1634. <https://doi.org/10.1016/j.cjca.2021.08.001>
326. Pepe, Salvatore, Ann T. Gregory, A. Robert Denniss, et al. 2021. "Myocarditis, Pericarditis and Cardiomyopathy after COVID-19 Vaccination." *Heart, Lung and Circulation* 30 (10): 1425–1429. <https://doi.org/10.1016/j.hlc.2021.07.011>
327. Bozkurt, Biykem, Ishan Kamat, and Peter J. Hotez. 2021. "Myocarditis with COVID-19 mRNA Vaccines." *Circulation* 144 (6): 471–484. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135>
328. Diaz, George A., Guilford T. Parsons, Sara K. Gering, et al. 2021. "Myocarditis and Pericarditis after Vaccination for COVID-19." *JAMA* 326 (12): 1210–1212. <https://jamanetwork.com/journals/jama/fullarticle/2782900>
329. Rosner, Carolyn M., et al. 2021. "Myocarditis Temporally Associated with COVID-19 Vaccination." *Circulation* 144 (6). <https://doi.org/10.1161/CIRCULATIONAHA.121.055891>
330. Jain, Supriya S., et al. 2021. "COVID-19 Vaccination–

- Associated Myocarditis in Adolescents." *Pediatrics* 148 (5). <https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf>
331. García, Javier Bautista, et al. 2021. "Acute Myocarditis after Administration of the BNT162b2 Vaccine against COVID-19." *Revista Espanola de Cardiologia (English Edition)* 74 (9): 802–814. <https://doi.org/10.1016/j.rec.2021.04.005>
332. Sulemankhil, Imran, et al. 2022. "Temporal Association between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review." *Cardiovascular Revascularization Medicine* 38: 117–123. <https://doi.org/10.1016/j.carrev.2021.08.012>
333. Nassar, Mahmoud, et al. 2021. "COVID-19 Vaccine-induced Myocarditis: Case Report with Literature Review." *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 15 (5). <https://doi.org/10.1016/j.dsx.2021.102205>
334. Shaw MD, Kirsten E., et al. 2021. "Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings." *JACC: Cardiovascular Imaging* 14 (9): 1856–1861. <https://doi.org/10.1016/j.jcmg.2021.06.002>
335. Minocha, Prashant K., et al. 2021. "Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent." *The Journal of Pediatrics* 238: 321–323. <https://doi.org/10.1016/j.jpeds.2021.06.035>
336. Abbate, Antonio, et al. 2021. "Fulminant Myocarditis and Systemic Hyperinflammation Temporally Associated with BNT162b2 mRNA COVID-19 Vaccination in Two Patients." *International Journal of Cardiology* 340: 119–121. <https://www.sciencedirect.com/science/article/pii/S0167527321012286>
337. Habib, Mhd Baraa, et al. 2021. "Acute Myocarditis following Administration of BNT162b2 Vaccine." *IDCases* 25. <https://doi.org/10.1016/j.idcr.2021.e01197>
338. Williams, Curtis B., Jung-in Choi, et al. 2021. "Acute Myocarditis following mRNA-1273 SARS-CoV-2 Vaccination." *CJC Open* 3 (11): 1410–1412. <https://doi.org/10.1016/j.cjco.2021.07.008>
339. Dickey, John B., Elisabeth Albert, Mai Badr, et al. 2021. "A Series of Patients with Myocarditis following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2." *JACC: Cardiovascular Imaging* 14 (9): 1862–1863. <https://doi.org/10.1016/j.jcmg.2021.06.003>
340. Singh, Balraj, et al. 2021. "COVID-19 mRNA Vaccine and Myocarditis." *European Journal of Case Reports in Internal Medicine* 8 (6). https://doi.org/10.12890/2021_002681

341. Salah, Husam M., and Jawahar L. Mehta. 2021. "COVID-19 Vaccine and Myocarditis." *American Journal of Cardiology* 157: 146–148. <https://doi.org/10.1016/j.amjcard.2021.07.009>
342. Park, Hwanhee, et al. 2021. "Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: A Multicenter Study." *Journal of Korean Medical Science* 36 (32). <https://doi.org/10.3346%2Fjkms.2021.36.e232>
343. Kerneis, Mathieu, et al. 2021. "COVID-19 Vaccines and Myocarditis." *Archives of Cardiovascular Diseases* 114 (6-7): 515–517. <https://doi.org/10.1016/j.acvd.2021.06.001>
344. Vidula, Mahesh K., et al. 2021. "Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines." *Cureus* 13 (6). <https://doi.org/10.7759/cureus.15576>
345. Pepe, Salvatore, Ann T. Gregory, A. Robert Denniss, et al. 2021. "Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination." *Heart, Lung and Circulation* 30 (10): 1425–1429. <https://doi.org/10.1016/j.hlc.2021.07.011>
346. Bozkurt, Biykem, Ishan Kamat, and Peter J. Hotez. 2021. "Myocarditis With COVID-19 mRNA Vaccines." *Circulation* 144 (6): 471–484. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135>
- 347.
1. "Association of Myocarditis with mRNA COVID-19 Vaccine in Children." *JAMA Cardiology*. <https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-covid-19-vaccine-in-children/>
348. Dionne, Audrey, Francesca Sperotto, Stephanie Chamberlain, et al. 2021. "Association of Myocarditis with BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children." *JAMA Cardiology* 6 (12): 1446–1450. <https://doi.org/10.1001/jamacardio.2021.3471>
349. Shay, David K., T. T. Shimabukuro, and F. DeStefano. 2021. "Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines." *JAMA Cardiology* 6 (10): 1115–1117. <https://doi.org/10.1001/jamacardio.2021.2821>
350. Verma MD, Amanda K., et al. 2021. "Myocarditis after Covid-19 mRNA Vaccination." *The New England Journal of Medicine* 385: 1332–1334. <https://doi.org/10.1056/NEJMc2109975>
351. Kim, Han W., Elizabeth R. Jenista, et al. 2021. "Patients with Acute Myocarditis following mRNA COVID-19 Vaccination." *JAMA Cardiology* 6 (10): 1196–1201. <https://jamanetwork.com/journals/jamacardiology/fullarticle/27>

[81602](#)

352. Starekova, Jitka, et al. 2021. "Myocarditis Associated with mRNA COVID-19 Vaccination." *Radiology* 301 (2). <https://doi.org/10.1148/radiol.2021211430>
353. Wong, Peter D., et al. 2021. "Clinical Guidance for Youth with Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination." Canadian Paediatric Society. September 1. <https://cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis>
354. 1. "COVID-19 Vaccine-associated Myocarditis/Pericarditis: A Report of the Chief Science Advisor of Canada." Office of the Chief Science Advisor of Canada. July 16. <https://science.gc.ca/site/science/en/office-chief-science-advisor/covid-19-vaccine-associated-myocarditispericarditis>
355. Viskin, Dana, et al. 2021. "Myocarditis Associated with COVID-19 Vaccination: Echocardiography, Cardiac Tomography, and Magnetic Resonance Imaging Findings." *Circulation: Cardiovascular Imaging* 14 (9). <https://doi.org/10.1161/CIRCIMAGING.121.013236>
356. 1. "Physicians for Informed Consent COVID-19 Vaccine Mandates: 21 Scientific Facts That Challenge the Assumptions, Vaccine Risk Statement (VRS)." Physicians for Informed Consent. November. <https://physiciansforinformedconsent.org/COVID-19-Vaccine-Mandates.pdf>
357. Shitrit, P., N. S. Zuckerman, O. Mor, B. S. Gottesman, and M. Chowers. 2021. "Nosocomial Outbreak Caused by the SARS-CoV-2 Delta Variant in a Highly Vaccinated Population, Israel, July 2021." *Euro Surveillance* 26 (39). <https://doi.org/10.2807/1560-7917.es.2021.26.39.2100822>
358. Brown, C.M., et al. 2021. "Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings—Barnstable County, Massachusetts, July 2021." *MMWR: Recommendations and Reports* 70 (31): 1059–1062. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm>
359. Subramanian, S. V., and A. Kumar. 2021. "Increases in COVID-19 Are Unrelated to Levels of Vaccination Across 68 Countries and 2947 Counties in the United States." *European Journal of Epidemiology* 36: 1237–1240. <https://doi.org/10.1007/s10654-021-00808-7>
360. 1. "FDA Briefing Document: Moderna COVID-19 Vaccine."

- fda.gov. December
17. <https://www.fda.gov/media/144434/download>
361. 1. "FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19." fda.gov. February 26. <https://www.fda.gov/media/146217/download>
362. 1. "FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine." fda.gov. December 10. <https://www.fda.gov/media/144245/download>
363. Centers for Disease Control and Prevention. 2024. "COVID Data Tracker: Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC, By State/Territory." cdc.gov. https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths
364. Fraiman, J., et al. 2022. "Serious Adverse Events of Special Interest following mRNA COVID-19 Vaccination in Randomized Trials in Adults." *Vaccine* (2022) 40 (40): 5798–805. <https://doi.org/10.1016/j.vaccine.2022.08.036>
365. 1. "Pfizer-BioNTech COVID-19 Vaccine: Emergency Use Authorization (EUA) Amendment for an Unapproved Product Review Memorandum—EUA 27034 (Amendment 132)." fda.gov. April 9. <https://www.fda.gov/media/148542/download>
366. 1. "FDA Briefing Document: EUA Amendment Request for Pfizer-BioNTech COVID-19 Vaccine for Use in Children 5 through 11 Years of Age." fda.gov. October 26. <https://www.fda.gov/media/153447/download>
367. Wallace, Megan. 2021. "ACIP COVID-19 Vaccines Work Group: Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine." cdc.gov. May 12. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/03-COVID-Wallace-508.pdf>
368. Centers for Disease Control and Prevention. 2021. "Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12–15 Years." cdc.gov. May 14. <https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-pfizer-biontech-vaccine-12-15-years.html#table03d>
369. Pfizer. 2023. "Downloadable Archived Fact Sheets for Healthcare Providers, Recipients and Caregivers for Pfizer-BioNTech COVID-19 Vaccine (through Summer 2023)." fda.gov. <https://www.fda.gov/media/167193/download>

- 370.
1. "Physicians for Informed Consent Education: COVID-19 Vaccines." Physicians for Informed Consent. <https://physiciansforinformedconsent.org/covid-19-vaccines/>
371. Centers for Disease Control and Prevention. 2023. "Weekly Updates by Select Demographic and Geographic Characteristics: Provisional Death Counts for Coronavirus Disease (COVID-19)." cdc.gov. September 27. https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex
372. Petersen, Maria Skaalum, Cecilie Bo Hansen, Marnar Friheim Kristiansen, Jógvan Páll Fjallsbak, et al. 2021. "SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study from the Faroe Islands." *Open Forum Infectious Diseases* 8 (8). <https://doi.org/10.1093/ofid/ofab378>
373. Haveri, Anu, Nina Ekström, Anna Solastie, Camilla Virta, et al. 2021. "Persistence of Neutralizing Antibodies a Year after SARS-CoV-2 Infection in Humans." *European Journal of Immunology* 51 (12): 3202–3213. <https://doi.org/10.1002/eji.202149535>
374. Zhang, Jie, Hao Lin, Beiwei Ye, Min Zhao, et al. 2022. "One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents." *Clinical Infectious Diseases* 75 (1): 1072–1081. <https://doi.org/10.1093/cid/ciab884>
375. Canaday, David H., Oladayo A. Oyebanji, Debbie Keresztesy, Michael Payne, et al. 2022. "Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination." *Clinical Infectious Diseases* 75 (1): 884–887. <https://academic.oup.com/cid/article/75/1/e884/6432026>
376. Suthar, Mehul S., Prabhu S. Arunachalam, Mengyun Hu, Noah Reis, et al. 2022. "Durability of Immune Responses to the BNT162b2 mRNA Vaccine." *Med* 3 (1): 25–27. <https://doi.org/10.1016/j.medj.2021.12.005>
377. Doria-Rose, Nicole, Mehul S. Suthar, et al. 2021. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." *The New England Journal of Medicine* 384 (23): 2259–2261. <https://doi.org/10.1056/nejmc2103916>
378. Cohen, Kristen W., Susanne L. Linderman, Zoe Moodie, et al. 2021. "Longitudinal Analysis Shows Durable and Broad Immune Memory after SARS-CoV-2 Infection with Persisting Antibody Responses and Memory B and T Cells." *Cell Reports Medicine* 2 (7). <https://doi.org/10.1016/j.xcrm.2021.100354>
379. Hammond, Jeremy R. 2021. "Antibodies Persist with Natural

- Immunity to SARS-CoV-2." Jeremy R. Hammond. October 11. <https://www.jeremyrhammond.com/2021/10/11/antibodies-persist-with-natural-immunity-to-sars-cov-2/>
380. Israel, Ariel, Yotam Shenhar, Ilan Green, Eugene Merzon, et al. 2022. "Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection." *Vaccines* 10 (1): 64. <https://doi.org/10.3390/vaccines10010064>
381. Eyran, Tsuf, Anna Vaisman-Mentesh, David Taussig, et al. 2022. "Longitudinal Kinetics of RBD+ Antibodies in COVID-19 Recovered Patients over 14 Months." *PLoS Pathogens* 18 (6). <https://doi.org/10.1371/journal.ppat.1010569>
382. Aldén, Markus, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, et al. 2022. "Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line." *Current Issues in Molecular Biology* 44 (3): 1115–1126. <https://www.mdpi.com/1467-3045/44/3/73>
383. WBALTV11. 2015. "Possible Measles Case in a 12-month-old from Baltimore Health: Officials Taking Precaution." January 24. <https://www.wbalTV.com/article/possible-measles-case-in-a-12-month-old-from-baltimore/7091459>
384. Hendriks, Jan, and Stuart Blume. 2013. "Measles Vaccination before the Measles-Mumps-Rubella Vaccine." *American Journal of Public Health (AJPH)* 103 (8): 1393–1401. <https://doi.org/10.2105/AJPH.2012.301075>
385. Langmuir, Alexander D., et al. 1962. "The Importance of Measles as a Health Problem." *American Journal of Public Health (AJPH)* 52 (Suppl 2): 1–4. https://doi.org/10.2105/ajph.52.suppl_2.1
386. Rowhani-Rahbar, Ali, Bruce Fireman, Edwin Lewis, et al. 2013. "Effect of Age on the Risk of Fever and Seizures following Immunization with Measles-Containing Vaccines in Children." *JAMA Pediatrics* 167 (12): 1111–1117. <https://doi.org/10.1001/jamapediatrics.2013.2745>
387. Merck & Co., Inc. 2023. "Package Insert—M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live)." [fda.gov. https://www.fda.gov/media/75191/download](https://www.fda.gov/media/75191/download)
388. Merck & Co., Inc. 2023. "Package Insert—M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live)." [fda.gov. https://www.fda.gov/media/75191/download](https://www.fda.gov/media/75191/download)
389. Riazi, K., M. Galic, B. Kuzmiski, W. Ho, K. Sharkey, Q. Pittman. 2008. "Microglial Activation and TNF α Production Mediate Altered CNS Excitability following Peripheral Inflammation." *Proceedings of the National Academy of Sciences of the United States of America*. 8:2008; 105(44):17151–17156. Holzer, P., A. Farzi, A. M. Hassan, G. Zenz, A. Jačan, and F. Reichmann F.

2017. "Visceral Inflammation and Immune Activation Stress the Brain." *Frontiers in Immunology*. 2017 Nov 22;8:1613. doi: 10.3389/fimmu.2017.01613. Rodriguez Juan I., and Janet K. Kern.
2011. "Evidence of Microglial Activation in Autism and Its Possible Role in Brain Underconnectivity." *Neuron Glia Biology* 2011;7(2-4):205–213. doi:10.1017/S1740925X12000142.
- 390.
1. "August 27, 2014 Press Release, 'Statement of William W. Thompson, Ph.D., regarding the 2004 Article Examining the Possibility of a Relationship between MMR Vaccine and Autism'." legislature.vermont.gov. August 27. <https://legislature.vermont.gov/Documents/2016/WorkGroups/House%20Health%20Care/Bills/H.98/Witness%20Testimony/H.98~Jennifer%20Stella~William%20Thompson%20Statement~5-6-2015.pdf>
391. Hooker, Brian S. 2014. "Measles-Mumps-Rubella Vaccination Timing and Autism Among Young African American Boys: A Reanalysis of CDC Data." *Translational Neurodegeneration* 3 (16). <https://doi.org/10.1186/2047-9158-3-16>
392. Bigtree, Del, and Andrew Wakefield. 2016. *VAXXED: From Cover-Up to Catastrophe*. Directed by Andrew Wakefield. Produced by Del Bigtree and Polly Tommey. <https://vaxxedthemovie.com/>
393. Merck & Co., Inc. 2023. "Package Insert—M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live)." fda.gov. <https://www.fda.gov/media/75191/download>
- 394.
1. "VAERS Data." Vaccine Adverse Event Reporting System (VAERS) on HHS.gov. <https://vaers.hhs.gov/data.html>
395. Centers for Disease Control and Prevention. 2024. "Measles Cases and Outbreaks." cdc.gov. February 23. <https://www.cdc.gov/measles/cases-outbreaks.html>
396. Centers for Disease Control and Prevention. 2024. "Measles Cases and Outbreaks." cdc.gov. February 23. <https://www.cdc.gov/measles/cases-outbreaks.html>
- 397.
1. "Physicians for Informed Consent Measles: Disease Information Statement (DIS)." Physicians for Informed Consent. <https://physiciansforinformedconsent.org/measles-disease-information-statement.pdf>
398. Barclay, A. J., A. Foster, and A. Sommer. 1987. "Vitamin A Supplements and Mortality Related to Measles: A Randomised Clinical Trial." *British Medical Journal (Clinical research ed.)* 294 (6567): 294–
296. <https://www.bmj.com/content/294/6567/294.abstract>
399. Wilson, Kumanan, Steven Hawken, Jeffrey C. Kwong,

- Shelley Deeks, et al. 2011. "Adverse Events following 12 and 18 Month Vaccinations: A Population-Based, Self-Controlled Case Series Analysis." *PLoS One* 6 (12). <https://doi.org/10.1371/journal.pone.0027897>
- 400.
1. "Mumps Clinical Information." Minnesota Department of Health. August
 1. <https://www.health.state.mn.us/diseases/mumps/hcp/clinical.html>
401. Deeks, Shelley L., Gillian H. Lim, Mary Anne Simpson, et al. 2011. "An Assessment of Mumps Vaccine Effectiveness by Dose During an Outbreak in Canada." *Canadian Medical Association Journal* 183 (9): 1014–1020. <https://doi.org/10.1503/cmaj.101371>
402. Seck, Hope Hodge. 2019. "Navy Ship Changes Schedule after Outbreak of Mumps-Like Disease Aboard." *Military.com*, March 15. <https://www.military.com/daily-news/2019/03/15/navy-ship-changes-schedule-after-outbreak-mumps-disease-aboard.html>
403. Dayan, Gustavo H., M. Patricia Quinlisk, Amy A. Parker, et al. 2008. "Recent Resurgence of Mumps in the United States." *The New England Journal of Medicine* 358: 1580–1589. <https://doi.org/10.1056/nejmoa0706589>
404. Barskey, Albert E., Cynthia Schulte, Jennifer B. Rosen, et al. 2012. "Mumps Outbreak in Orthodox Jewish Communities in the United States." *The New England Journal of Medicine* 367: 1704–1713. <https://www.nejm.org/doi/full/10.1056/nejmoa1202865>
- 405.
1. "United States ex rel Krahlung and Wlochowski v. Merck & Co., Case No. 10-cv-4374." Keller Grover. April 27. <https://www.kellergrover.com/cases/whistleblower-actions/active-cases-whistleblower-actions/united-states-ex-rel-krahlung-and-wlochowski-v-merck-co/>
- 406.
1. "United States v. Merck & Co., Civil Action 10-4374." Casetext, part of Thomson Reuters. July 27. <https://casetext.com/case/united-states-v-merck-co>
407. Centers for Disease Control and Prevention. 2024. "Mumps Cases and Outbreaks." *cdc.gov*. February 9. <https://www.cdc.gov/mumps/outbreaks.html>
408. Centers for Disease Control and Prevention. 2023. "Rubella in the U.S." *cdc.gov*. November 14. <https://www.cdc.gov/rubella/about/in-the-us.html>
409. Centers for Disease Control and Prevention. 2023. "Rubella in the U.S." *cdc.gov*. November 14. <https://www.cdc.gov/rubella/about/in-the-us.html>
410. Leung, Jessica, et al. 2022. "The Impact of Universal

- Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch." *The Journal of Infectious Diseases* 226 (Supplement 4): S470–S477. <https://doi.org/10.1093/infdis/jiac255>
411. Centers for Disease Control and Prevention. 2023. "Shingles Burden and Trends." cdc.gov. May 10. <https://www.cdc.gov/shingles/surveillance.html>
412. Goldman, G. S., and P. G. King. 2013. "Review of the United States Universal Varicella Vaccination Program: Herpes Zoster Incidence Rates, Cost-effectiveness, and Vaccine Efficacy Based Primarily on the Antelope Valley Varicella Active Surveillance Project Data." *Vaccine* 31 (13): 1680–1694. <https://doi.org/10.1016/j.vaccine.2012.05.050>
413. Centers for Disease Control and Prevention. 2022. "U.S. Chickenpox Vaccination Program." cdc.gov. <https://www.cdc.gov/chickenpox/vaccination-program-impact.html>
414. Centers for Disease Control and Prevention. 2022. "Viral Hepatitis Surveillance: Number of reported cases of hepatitis A virus infection and estimated infections—United States, 2013–2020." cdc.gov. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-a/figure-1.1.htm>
415. 1. "VAERS Data." Vaccine Adverse Event Reporting System (VAERS) on HHS.gov. <https://vaers.hhs.gov/data.html>
416. GlaxoSmithKline (GSK). 1995. "Package Insert: HAVRIX (Hepatitis A Vaccine) injectable suspension, for intramuscular use." fda.gov. <https://www.fda.gov/media/119388/download>
417. Merck & Co., Inc. 1996. "Package Insert: VAQTA® (Hepatitis A Vaccine, Inactivated)." fda.gov. <https://www.fda.gov/media/74519/download>
418. 1. "Cancer Stat Facts: Cervical Cancer." National Cancer Institute: Surveillance, Epidemiology, and End Results Program. <https://seer.cancer.gov/statfacts/html/cervix.html>
419. American Cancer Society. 2024. *Key Statistics for Cervical Cancer*. January 17. <https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html>
420. American Cancer Society. 2018. *Cancer Statistics Center*. <https://cancerstatisticscenter.cancer.org/>
421. Tomljenovic, Lucija, Jean Pierre Spinosa, and Christopher A. Shaw. 2013. "Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?" *Current Pharmaceutical Design* 19 (8): 1466–

1487. <https://pubmed.ncbi.nlm.nih.gov/23016780/>
- 422.
1. "NVIC Search Results From the 2/23/2024 Release of VAERS Data: Found 44,793 Adverse Event Cases Where Vaccine is IPV." MedAlerts.org, February 23. <https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUPI=CAT&GROUP2=SER&GRAPH=ON&GROUP6=CAT&EVENTS=ON&VAX=IPV>
- 423.
1. "Human Papillomavirus (HPV) & HPV Vaccine Quick Facts." National Vaccine Information Center (NVIC). February 22. <https://www.nvic.org/disease-vaccine/hpv/quick-facts>
424. Tomljenovic, Lucija, Jean Pierre Spinosa, and Christopher A. Shaw. 2013. "Human Papillomavirus (HPV) (FDA 2007) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?" *Current Pharmaceutical Design* 19 (8): 1466–1487. <https://pubmed.ncbi.nlm.nih.gov/23016780/>
425. Colafrancesco, Serena, Carlo Perricone, Lucija Tomljenovic, and Yehuda Shoenfeld. 2013. "Human Papilloma Virus Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants." *American Journal of Reproductive Immunology* 70 (4): 309–316. <https://doi.org/10.1111/aji.12151>
426. Little, Deirdre Therese, and Harvey Rodrick Grenville Ward. 2014. "Adolescent Premature Ovarian Insufficiency following Human Papillomavirus Vaccination: A Case Series Seen in General Practice." *Journal of Investigative Medicine High Impact Case Reports* 2 (4). <https://doi.org/10.1177%2F2324709614556129>
427. Tatang, Collins, Teigna Arredondo Bisonó, Aureore Bergamasco, et al. 2021. "Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System." *Drugs—Real World Outcomes* 9: 79–90. <https://doi.org/10.1007/s40801-021-00271-6>
428. Merck & Co., Inc. 2014. "Package Insert: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)." fda.gov. <https://www.fda.gov/media/90064/download>
429. Merck & Co., Inc. 2015. "Package Insert: GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]." fda.gov. April. <https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---Gardasil.pdf>
430. Merck & Co., Inc. 2015. "Package Insert: GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]." fda.gov.

- April. <https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---Gardasil.pdf>
431. Merck & Co., Inc. 2014. "Package Insert: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)." fda.gov. <https://www.fda.gov/media/90064/download>
432. Merck & Co., Inc. 2014. "Package Insert: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)." fda.gov. <https://www.fda.gov/media/90064/download>
433. Hooker, Brian S. 2014. "Measles-Mumps-Rubella Vaccination Timing and Autism among Young African American Boys: A Reanalysis of CDC Data." *Translational Neurodegeneration* 3 (16). <https://doi.org/10.1186/2047-9158-3-16>
434. Attkisson, Sharyl. 2009. "Gardasil Researcher Speaks Out." CBS News Interactive Inc., August 19. <https://www.cbsnews.com/news/gardasil-researcher-speaks-out/>
435. Health Impact News Editor. 2014. "Merck's Former Doctor Predicts That Gardasil Will become the Greatest Medical Scandal of All Time." *Health Impact News*, April 15. <https://healthimpactnews.com/2014/mercks-former-doctor-predicts-that-gardasil-will-become-the-greatest-medical-scandal-of-all-time/>
436. Centers for Disease Control and Prevention. 2021. "Chapter 14: Meningococcal Disease Surveillance." In *Epidemiology and Prevention of Vaccine-Preventable Diseases 14th ed. (The Pink Book)*, edited by Penina Haber and Sarah Schillie. Washington, D.C.: Public Health Foundation. <https://www.cdc.gov/vaccines/pubs/pinkbook/mening.html>
437. Centers for Disease Control and Prevention. 2023. Meningococcal surveillance. cdc.gov via archive.org. October 23. <https://web.archive.org/web/20231023215117/https://www.cdc.gov/meningococcal/surveillance/>
438. Kennedy Jr., Robert F. 2015. "Robert F. Kennedy, Jr.: Doing the Math on Meningitis Vaccinations." *Daily Camera*, June 9. <https://www.dailycamera.com/2015/06/09/robert-f-kennedy-jr-doing-the-math-on-meningitis-vaccinations/>
439. ABC News. 2008. "Vaccines Seek to Offer Cradle-to-Grave Protection." ABC News, August 29. <https://abcnews.go.com/Health/Healthday/story?id=5689652&page=1>
440. O'Toole, Zoey, and Mary Holland editors. 2022. "Chapter 1 Turtles All the Way Down: Vaccine Clinical Trials." *Turtles All the Way Down: Vaccine Science and Myth*, 35–84. The Turtles Team.
441. Barberis, I., P. Myles, S. K. Ault, et al. 2016. "History and Evolution of Influenza Control through Vaccination: From the First

- Monovalent Vaccine to Universal Vaccines." *Journal of Preventive Medicine and Hygiene* 57 (3): E115–E120. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139605/>
442. FDA. 2007. "FluMist Prior Approval Supplemental BLA." fda.gov. April. <https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B1-02.pdf>
443. Falsey, Ann R., John J. Treanor, Nadia Torniepoorth, et al. 2009. "Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older." *The Journal of Infectious Diseases* 200 (2): 172–180. <https://doi.org/10.1086/599790>
444. FLCCC Alliance. 2023. "I-PREVENT COVID, Flu and RSV Protection Protocol." FLCCC Alliance. December 1. <https://covid19criticalcare.com/protocol/i-prevent-covid-flu-rsv/>
445. Centers for Disease Control and Prevention. 1996. "Chapter 16: Tetanus." In *Manual for the Surveillance of Vaccine-Preventable Diseases*, by Amy Blain and Tejpratap S. P. Tiwari. Atlanta, GA: National Center for Immunization and Respiratory Diseases. <https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html>
446. Tomljenovic, Lucija. 2011. "Aluminum and Alzheimer's Disease: After a Century of Controversy, Is There a Plausible Link?" *Journal of Alzheimer's Disease* 23 (4): 567–598. <https://doi.org/10.3233/JAD-2010-101494>
447. Centers for Disease Control and Prevention. 2019. "Influenza (Flu): How CDC Estimates the Burden of Seasonal Influenza in the U.S." cdc.gov. November 22. <https://www.cdc.gov/flu/about/burden/how-cdc-estimates.htm>
448. Centers for Disease Control and Prevention. 2024. "Influenza (Flu): Past Seasons Estimated Influenza Disease Burden." cdc.gov. February 28. <https://www.cdc.gov/flu/about/burden/past-seasons.html>
449. Centers for Disease Control and Prevention. 2024. "RSV Fact Sheet Older Adults." cdc.gov. April. <https://www.cdc.gov/rsv/factsheet-older-adults.pdf>
450. GlaxoSmithKline (GSK). 2023. "Package Insert: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) suspension for intramuscular injection." fda.gov. May. <https://www.fda.gov/media/167805/download>
451. GlaxoSmithKline (GSK). 2023. "Package Insert: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) suspension for intramuscular injection." fda.gov. May. <https://www.fda.gov/media/167805/download>
452. GlaxoSmithKline (GSK). 2023. "Package Insert: AREXVY

- (Respiratory Syncytial Virus Vaccine, Adjuvanted) suspension for intramuscular injection." fda.gov.
May. <https://www.fda.gov/media/167805/download>
453. GlaxoSmithKline (GSK). 2023. "Package Insert: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) suspension for intramuscular injection." fda.gov.
May. <https://www.fda.gov/media/167805/download>
454. Pfizer. 2024. "Package Insert: ABRYSVO (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use." fda.gov. March. <https://www.fda.gov/media/168889/download>
455. Pfizer. 2024. "Package Insert: ABRYSVO (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use." fda.gov. March. <https://www.fda.gov/media/168889/download>
456. Havers, Fiona P., Michael Whitaker, Michael Melgar, et al. 2023. "Characteristics and Outcomes Among Adults Aged ≥ 60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus—RSV-NET, 12 States, July 2022–June 2023." *MMWR: Recommendations and Reports* 72 (40): 1075–1082. <https://www.cdc.gov/mmwr/volumes/72/wr/mm7240a1.htm>
457. Centers for Disease Control and Prevention. 2023. "Shingles Burden and Trends." cdc.gov. May 10. <https://www.cdc.gov/shingles/surveillance.html>
458. Altukhaim, Feras, May Mutlaq, Mohammed Alghamdi, and Salha Hakami. 2023. "Reactivation of Herpes Zoster After Recombinant Vaccine (Shingrix): A Case Report." *Cureus* 15 (1). <https://doi.org/10.7759/cureus.34431>
459. GlaxoSmithKline (GSK). 2023. "Package Insert: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection." fda.gov.
May. <https://www.fda.gov/media/108597/download>
460. Scutti, Susan. 2019. "Shingles Vaccine Side Effects Mostly Mild, Yet 3% of Complaints Were Serious, CDC Says." *CNN Digital*, January 31. <https://www.cnn.com/2019/01/31/health/shingrix-shingles-vaccine-side-effects-report-cdc/index.html>
461. GlaxoSmithKline (GSK). 2023. "Package Insert: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection." fda.gov.
May. <https://www.fda.gov/media/108597/download>
462. Marin, Mona, Amy Parker Fiebelkorn, Daoling Bi, et al. 2021. "Adverse Events among Young Adults following a Third Dose of Measles-Mumps-Rubella Vaccine." *Clinical Infectious Diseases* 73 (7): e1546–e1553. <https://doi.org/10.1093/cid/ciaa1090>
463. Alonge, Oluwakemi D., Mona Marin, Carole J. Hickman, et al. 2024. "Long-term Neutralizing Antibody Levels against Measles

- and Rubella Viruses among Adults with 3 Doses of Measles-Mumps-Rubella Vaccine." *Open Forum Infectious Diseases* 11
 (1). <https://doi.org/10.1093/ofid/ofad700>
464. Kaaijk, Patricia, Alienke J. Wijmenga-Monsuur, Hinke I. ten Hulscher, et al. 2022. "Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults." *Vaccines* 10 (1):
 132. <https://doi.org/10.3390/vaccines10010132>
465. Fiebelkorn, Amy Parker, Laura A. Coleman, Edward A. Belongia, et al. Fall 2014. "Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine." *Open Forum Infectious Diseases* 1
 (3). <https://doi.org/10.1093/ofid/ofu094>
466. Diep, Francie. 2014. "100 Years of Smoking Studies in Popular Science." *Popular Science*, January
 10. <https://www.popsoci.com/article/science/100-years-smoking-studies-popular-science/>
467.
 1. "The 5 Ways Tobacco Companies Lied About the Dangers of Smoking Cigarettes." Truth Initiative. December
 21. <https://truthinitiative.org/research-resources/tobacco-prevention-efforts/5-ways-tobacco-companies-lied-about-dangers-smoking>
468. History.com Editors. 2009. "President Nixon signs legislation banning cigarette ads on TV and radio."
 History.com. <https://www.history.com/this-day-in-history/nixon-signs-legislation-banning-cigarette-ads-on-tv-and-radio>
469.
 1. "List of Largest Pharmaceutical Settlements."
 Wikipedia. https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_settlements
470. Pfizer. 2023. "Stories & News: A Record-Breaking Year and Strong Fourth Quarter for Pfizer." Pfizer Investor Insights. January
 31. <https://insights.pfizer.com/fourth-quarter-fy-earnings/>
471. Wakefield, Andrew J., S. H. Murch, A. Anthony, J. Linnell, D. M. Casson, M. Malik, M. Berelowitz, et al. 1998. "Ileal-lymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in Children." *The Lancet* 351 (9103): 637–
 641. [https://doi.org/10.1016/S0140-6736\(97\)11096-0](https://doi.org/10.1016/S0140-6736(97)11096-0)
472. Walker, Stephen J., John Fortunato, Lenny G. Gonzalez, and Arthur Krigsman. 2013. "Identification of Unique Gene Expression Profile in Children with Regressive Autism Spectrum Disorder (ASD) and Ileocolitis." *PLoS One* 8
 (3). <https://doi.org/10.1371/journal.pone.0058058>
473. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative

- Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
474. Classen, John B., and David C. Classen. 2003. "Clustering of Cases of Type 1 Diabetes Mellitus Occurring 2–4 Years after Vaccination is Consistent with Clustering after Infections and Progression to Type 1 Diabetes Mellitus in Autoantibody Positive Individuals." *Journal of Pediatric Endocrinology and Metabolism* 16 (4): 495–508. <https://pubmed.ncbi.nlm.nih.gov/12793601/>
475. DeStefano, Frank, Tanya Karapurkar Bhasin, William W. Thompson, Marshalyne Yeargin-Allsopp, and Coleen Boyle. 2004. "Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta." *Pediatrics* 113 (2): 259–266. <https://doi.org/10.1542/peds.113.2.259>
476. Mawson, Anthony R., Brian D. Ray, Azad R Bhuiyan, and Binu Jacob. 2017. "Pilot Comparative Study on the Health of Vaccinated and Unvaccinated 6- to 12-year-old U.S. Children." *Journal of Translational Science* 3 (3): 1–12. <https://doi.org/10.15761/JTS.1000186>
477. Hooker, Brian S., and Neil Z. Miller. 2020. "Analysis of Health Outcomes in Vaccinated and Unvaccinated Children: Developmental Delays, Asthma, Ear Infections and Gastrointestinal Disorders." *SAGE Open Medicine* 8. <https://doi.org/10.1177%2F2050312120925344>
478. Hooker, Brian S. 2014. "Measles-Mumps-Rubella Vaccination Timing and Autism among Young African American Boys: A Reanalysis of CDC Data." *Translational Neurodegeneration* 3 (16). <https://doi.org/10.1186/2047-9158-3-16>
479. Aaby, Peter, Henrik Jensen, et al. 2004. "The Introduction of Diphtheria-Tetanus-Pertussis Vaccine and Child Mortality in Rural Guinea-Bissau: An Observational Study." *International Journal of Epidemiology* 33 (2): 374–380. <https://academic.oup.com/ije/article/33/2/374/715842>
480. Kennedy Jr., Robert F., and Brian Hooker. 2023. *Vax-Unvax: Let the Science Speak*. Skyhorse Publishing.
481. Aaby, Peter, Henrik Ravn, Adam Roth, et al. 2012. "Early Diphtheria-Tetanus-Pertussis Vaccination Associated with Higher Female Mortality and No Difference in Male Mortality in a Cohort of Low Birthweight Children: An Observational Study within a Randomised Trial." *Archives of Disease in Childhood* 97 (8): 685–691. <https://adc.bmj.com/content/97/8/685>
482. Kennedy Jr., Robert F., and Brian Hooker. 2023. *Vax-Unvax: Let the Science Speak*. Skyhorse Publishing.

483. Mogensen, Søren Wengel, Andreas Andersen, et al. 2017. "The Introduction of Diphtheria-Tetanus-Pertussis and Oral Polio Vaccine among Young Infants in an Urban African Community: A Natural Experiment." *EBioMedicine* 17: 192–198. <https://doi.org/10.1016/j.ebiom.2017.01.041>
484. Geier, David A., Janet K. Kern, and Mark R. Geier. 2019. "A Cross-sectional Study of the Relationship Between Reported Human Papillomavirus Vaccine Exposure and the Incidence of Reported Asthma in the United States." *SAGE Open Medicine* 7. <https://doi.org/10.1177/2050312118822650>
485. Mawson, Anthony R., Brian D. Ray, Azad R Bhuiyan, and Binu Jacob. 2017. "Pilot Comparative Study on the Health of Vaccinated and Unvaccinated 6- to 12-year-old U.S. Children." *Journal of Translational Science* 3 (3): 1–12. <https://doi.org/10.15761/JTS.1000186>
486. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
487. Lyons-Weiler, James, and Russell L. Blaylock. 2022. "Revisiting Excess Diagnoses of Illnesses and Conditions in Children Whose Parents Provided Informed Permission to Vaccinate Them." *International Journal of Vaccine Theory, Practice, and Research* 2 (2): 603–618. <http://dx.doi.org/10.56098/ijvtp.v2i2.59>
488. Thomas MD, Paul, and Jennifer Margulis PhD. 2016. *The Vaccine-Friendly Plan: Dr. Paul's Safe and Effective Approach to Immunity and Health—From Pregnancy Through Your Child's Teen Years*. New York: Ballantine Books.
489. Lyons-Weiler, James, and Paul Thomas. 2020. "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination." *International Journal of Environmental Research and Public Health* 17 (22): 8674. <https://doi.org/10.3390/ijerph17228674>
490. Cao, Zheng, Xu Yang, Haiyang Zhang, Haoran Wang, Wanyue Huang, Feibo Xu, Cuicui Zhuang, Xiaoguang Wang, and Yanfei Li. 2016. "Aluminum Chloride Induces Neuroinflammation, Loss of Neuronal Dendritic Spine and Cognition Impairment in Developing Rat." *Chemosphere* 151: 289–295. <https://www.sciencedirect.com/science/article/abs/pii/S0045653516302533>
491. Choi, Gloria B., Yeong S. Yim, Helen Wong, Sangdo Kim, et al. 2016. "The Maternal Interleukin-17a Pathway in Mice Promotes Autism-like Phenotypes in Offspring." *Science* 351 (6276): 933–939. <https://www.science.org/doi/10.1126/science.aad0314>

492. Al-Ayadhi, Laila Yousef, and Gehan Ahmed Mostafa. 2012. "Elevated Serum Levels of Interleukin-17A in Children with Autism." *Journal of Neuroinflammation* 9 (158). <https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-158>
493. Akintunde, Marjannie Eloi, Melissa Rose, Paula Krakowiak, Luke Heuer, Paul Ashwood, Robin H. Hansen, Irva Hertz-Picciotto, and Judy Van de Water. 2015. "Increased Production of IL-17 in Children with Autism Spectrum Disorders and Co-morbid Asthma." *Journal of Neuroimmunology* 286: 33–41. [https://www.jni-journal.com/article/S0165-5728\(15\)30004-7/abstract30004-7/abstract](https://www.jni-journal.com/article/S0165-5728(15)30004-7/abstract30004-7/abstract)
494. Ogura, Hideki, et al. 2013. "The Gateway Theory: How Regional Neural Activation Creates a Gateway for Immune Cells via an Inflammation Amplifier." *Journal of Biomedical Science* 36 (6). <https://doi.org/10.4103/2319-4170.113187>
495. Hooker, Brian S., and Neil Z. Miller. 2020. "Analysis of Health Outcomes in Vaccinated and Unvaccinated Children: Developmental Delays, Asthma, Ear Infections and Gastrointestinal Disorders." *SAGE Open Medicine* 8. <https://doi.org/10.1177%2F2050312120925344>
496. Hooker, Brian S., and Neil Z. Miller. 2021. "Health Effects in Vaccinated Versus Unvaccinated Children, with Covariates for Breastfeeding Status and Type of Birth." *Journal of Translational Science* 7 (1–11). <https://www.oatext.com/pdf/JTS-7-459.pdf>
497. Kennedy Jr., Robert F., and Brian Hooker. 2023. *Vax-Unvax: Let the Science Speak*. Skyhorse Publishing.
498. Blaylock, R. L., and Joseph Maroon. 2012. "Natural Plant Products and Extracts That Reduce Immunoexcitotoxicity-Associated Neurodegeneration and Promote Repair within the Central Nervous System." *Surgical Neurology International* 3: 19. <https://pubmed.ncbi.nlm.nih.gov/22439110/>
499. Shoenfeld, Yehuda, Nancy Agmon-Levin, and Lucija Tomljenovic. 2015. *Vaccines and Autoimmunity*. Wiley-Blackwell.
- 500.
1. "Blog Post: What Is the Mother Fucker (MTHFR) Mutation? MTHFR." One Percent with Francesca. July 3. <https://onepercentnet.wordpress.com/2017/07/03/what-is-the-mother-fucker-mthfr-mutation-mthfr/>
501. Lynch ND, Ben. 2018. *Dirty Genes: A Breakthrough Program to Treat the Root Cause of Illness and Optimize Your Health*. 1st edition. HarperOne.
502. Centers for Disease Control and Prevention. 2024. "Traveler's Health." cdc.gov. <https://wwwnc.cdc.gov/travel>
503. American Academy of Allergy Asthma & Immunology

(AAAAI). 2020. *Immunosuppressive Medication for the Treatment of Autoimmune Disease*. September

28. <https://www.aaaai.org/conditions-treatments/related-conditions/immunosuppressive>

504.

1. "Judicial Notice: Numerical Risk Comparison of Non-vaccination Versus Vaccination." vaxcheckers.org. September. <https://vaxcheckers.org/wp-content/uploads/2021/09/PRJN4.pdf>